| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Halozyme Therapeutics, Inc.$76.2
-2.63 (-3.35%)
B 65Pipeline Score Undervalued Biotech · Commercial
Market Cap
8.10 B
EPS
2.92
P/E Ratio
24.57 $
Value Trade
148.85 M
SEC Financials
Q1 2026Dilution Risk
Revenue
376.71 M
R&D Expenses
25.56 M
Operating CF
180.08 M
Total Assets
2.67 B
Total Liabilities
2.45 B
Equity
219.64 M
D/E Ratio
12,345
-1.29 %
Week
-0.71 %
1 Month
-4.73 %
3 Month
-0.94 %
6 Month
57.75 %
5 Year
1,721.87 %
All Time
Cash Data
Cash Position
318.62 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
1.47 M
52 Week Range
51.06 - 82.22
% held by Insiders
1.05 %
% held by Institutions
105.06 %
Enterprise Value
9.93 B
Total Shares
118.61 M
Short %
11.46 %
Float Shares
115.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Halozyme Therapeutics, Inc.
1131Total events
7Upcoming
404Tier-1 (high impact)
2010 – 2030Coverage
Upcoming catalysts 7
Dec 2026
T2Trial Initiation
Two of Elektrofi's partners projected to begin Hypercon formulated product clinical development by year end 2026 or earlier
2026
T2Quarterly Update
Raised 2026 total revenue guidance to $1,710-$1,810M, royalty revenue $1,130-$1,170M
2026
T1Partnership / License
Expects to sign three or more new drug delivery licensing agreements by end of 2026
TBD
T1IP Litigation Ruling
Halozyme sues Merck in U.S. federal district court in New Jersey for patent infringement of 15 MDASE patents
Event history 1124
Jun 15, 2026
▲Timing GuidancePresentation
Halozyme projects zero to minimal royalty revenue impact through at least 2035 based on CMS proposed rule
Jun 8, 2026
May 11, 2026
May 11, 2026
▲FDA ApprovalFDA Decision
FDA approved VYVGART Hytrulo for all serotypes of generalized myasthenia gravis
generalized myasthenia gravis (all serotypes)source ↗
May 11, 2026
▲Topline ReadoutClinical Data
Positive Phase 3 data in ocular myasthenia gravis
ocular myasthenia gravissource ↗
May 11, 2026
▲FDA ApprovalFDA Decision
DARZALEX Faspro gained 12th and 13th approved indications in multiple myeloma
newly diagnosed and early second line multiple myelomasource ↗
May 11, 2026
▲Topline ReadoutTAK-881Clinical Data
Positive Phase 2/3 data for TAK-881 in primary immune deficiency
primary immune deficiencysource ↗
May 11, 2026
▲Equity OfferingCorporate
Announced new $1 billion share repurchase program, projecting at least $400 million in 2026
May 7, 2026
▲Partnership / LicenseCorporate
Halozyme enters global collaboration and license agreement with GSK for ENHANZE technology in multiple oncology targets including ADCs
oncologysource ↗
May 6, 2026
▲Partnership / LicenseCorporate
Halozyme and Oruka announce global collaboration and license agreement for Hypercon technology with ORKA-001
Apr 7, 2026
▲Partnership / LicenseCorporate
Global exclusive collaboration and license agreement with Vertex for Hypercon technology
Drug Pipeline Intelligence
B65
Pipeline Score $10.8B
Pipeline ValueUndervalued
Valuation Signal12
Drugs Scored4.5x
rNPV / MCap Top 92%
Small Cap (rank 74 of 911)
Percentile RankHalozyme Therapeutics, Inc. holds a solid B-grade pipeline (65/100), with $16.6B risk-adjusted pipeline value, led by Humalog in Type 1 Diabetes Mellitus (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humalog Small molecule | Type 1 Diabetes Mellitus | Phase 2 | NCT00774800 | 23% | $4.7B | COMPLETED | 22 | - | - | Mar 1, 2009 | - | Feb 26, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TECVAYLI | relapsed or refractory multiple myeloma | Phase 3 | 2026-03-06 | 83% reduction in the risk of disease progression or death compared to standard regimens (hazard ratio [HR], 0.17; 95 percent confidence interval [CI], 0.12-0.23; P<0.0001); three-year PFS rate was 83% Read More | U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma Read More | |
TECVAYLI | relapsed or refractory multiple myeloma | Phase 3 | 2026-03-06 | 83% reduction in the risk of disease progression or death compared to standard regimens (hazard ratio [HR], 0.17; 95 percent confidence interval [CI], 0.12-0.23; P<0.0001); three-year PFS rate was 83% Read More | U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma Read More | |
TECVAYLI | relapsed or refractory multiple myeloma | Phase 3 | 2026-03-06 | 83% reduction in the risk of disease progression or death compared to standard regimens (hazard ratio [HR], 0.17; 95 percent confidence interval [CI], 0.12-0.23; P<0.0001); three-year PFS rate was 83% Read More | U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HALO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HALO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HALOHalozyme Appoints David Ramsay as President Drug Delivery
Halozyme Therapeutics has appointed David Ramsay as President of Drug Delivery, effective June 30, 2026. In this newly created position, Ramsay will oversee the growth of the company's drug delivery technologies. He brings over 30 years of experience in financial leadership within the biotechnology sector, having previously served as Halozyme's CFO. Ramsay aims to enhance value creation for shareholders through strategic initiatives.
Read more →HALOHalozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Halozyme Therapeutics has confirmed that it anticipates zero to minimal impact on its royalty revenues through at least 2035, following an analysis of the proposed Medicare Drug Price Negotiation Program rule. The company remains optimistic about its ENHANZE partnership agreements and the continued applicability of orphan drug protections. Halozyme aims to engage with CMS to support favorable policies for innovation and patient access.
Read more →HALO▲ +6.8%on this news
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics reported a strong financial performance for Q1 2026, with a 42% increase in total revenue to $377 million. The company announced a $1 billion share repurchase program and reiterated its 2026 financial guidance, projecting total revenue between $1.710 billion and $1.810 billion. Recent collaborations with Vertex, Oruka, and GSK highlight the growing interest in Halozyme's drug delivery technologies.
Read more →HALOHalozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Halozyme Therapeutics has entered a global collaboration with GSK to develop subcutaneous formulations for multiple oncology targets, including antibody drug conjugates. This agreement marks the first use of Halozyme's ENHANZE technology for ADCs, aiming to enhance patient treatment experiences. The first clinical trial is expected to begin in 2026, with potential royalties for Halozyme from future sales.
Read more →HALOHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology Halozyme Therapeutics, Inc. (Nasdaq: HALO) ( Halozyme ) and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ( Oruka ) today announced that Halozyme's...
Halozyme Therapeutics and Oruka Therapeutics have formed a global collaboration to develop ORKA-001 using Halozyme's Hypercon™ technology, focusing on psoriasis and related inflammatory diseases. The agreement grants Oruka exclusive rights to utilize Halozyme's microparticle technology, which enhances drug delivery by reducing injection volume. Oruka will make an upfront payment and potential milestone payments to Halozyme, which will also receive royalties on sales. This partnership marks a significant step toward improving treatment options for patients with chronic skin conditions.
Read more →HALOHalozyme to Report First Quarter 2026 Financial and Operating Results
Halozyme Therapeutics, Inc. will release its first quarter 2026 financial and operating results on May 11, 2026. A conference call will follow the results announcement, allowing stakeholders to discuss the outcomes. The company continues to innovate in drug delivery technologies, enhancing patient experiences and outcomes.
Read more →HALOHalozyme Appoints Darren Snellgrove as Chief Financial Officer
Halozyme Therapeutics has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Snellgrove, who has over 30 years of experience in financial leadership, will oversee financial operations and strategy. His previous role at Johnson & Johnson involved reshaping investor relations and corporate messaging. This appointment is seen as a strategic move to drive growth and shareholder value.
Read more →HALOHalozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
Halozyme Therapeutics has entered a global collaboration with Vertex Pharmaceuticals to license its Hypercon technology, which allows for hyperconcentration of drugs. This partnership aims to improve patient access to biologics by reducing injection volume and enabling at-home administration. Vertex will pay Halozyme $15 million upfront, with additional milestone payments and royalties on sales.
Read more →HALOHalozyme Appoints David Ramsay as Interim Chief Financial Officer
Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay, who has over 30 years of experience in financial leadership, previously served as CFO of Halozyme and played a significant role in the company's growth. The search for a permanent CFO is actively underway.
Read more →HALOU.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
Halozyme Therapeutics announced that the FDA has approved TECVAYLI in combination with DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma. This approval is based on Phase 3 data showing significant improvements in progression-free survival and overall survival compared to standard treatments. The new regimen offers a convenient subcutaneous administration method for patients.
Read more →HALOHalozyme to Participate in Upcoming Investor Conferences
Halozyme Therapeutics, Inc. announced that Dr. Helen Torley will present and host investor meetings at upcoming conferences. The company is known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of medications. Halozyme's innovative solutions aim to enhance patient experiences and outcomes, with a significant impact on the biopharmaceutical landscape.
Read more →HALOHALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increase
Halozyme Therapeutics reported record revenues for the full year 2025, totaling $1.4 billion, a 38% increase from the previous year. The company's royal revenue surged by 52% to $868 million, driven by successful collaborations with major pharmaceutical partners. Halozyme reaffirmed its strong financial guidance for 2026, projecting total revenue between $1.710 and $1.810 billion. The acquisitions of Elektrofi and Surf Bio's technology portfolios are expected to enhance the company's drug delivery capabilities and long-term revenue potential.
Read more →HALOHalozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
Halozyme Therapeutics, Inc. will release its fourth quarter and full year 2025 financial results on February 17, 2026. A conference call will follow the release to discuss the results. The company is recognized for its innovative drug delivery solutions and has expanded its technology portfolio with new partnerships.
Read more →HALOHalozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
Halozyme Therapeutics has raised its revenue estimates for 2025 and 2026, forecasting significant growth in total and royalty revenues. The company also announced the acquisition of Surf Bio, enhancing its drug delivery capabilities. The CEO emphasized the strong momentum and strategic partnerships that support long-term growth and shareholder value.
Read more →HALOHalozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update Halozyme Therapeutics, Inc. (Nasdaq: HALO) ( Halozyme ) today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at...
Halozyme Therapeutics, Inc. announced it will host an Investor Conference Call on January 28, 2026, to discuss updated financial guidance and provide preliminary revenue results for 2025. During the call, CEO Dr. Helen Torley and CFO Nicole LaBrosse will present insights into the company's financial outlook for 2026 to 2028 and discuss ongoing business developments. Halozyme continues to innovate in drug delivery technologies, notably ENHANZE® and Hypercon™, aimed at improving patient care and treatment convenience.
Read more →HALOHalozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive license agreement with...
Halozyme Therapeutics has entered into a global collaboration and exclusive license agreement with Takeda to utilize its ENHANZE drug delivery technology with vedolizumab, known as ENTYVIO. This partnership aims to provide enhanced treatment options for patients suffering from inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. Takeda will pay Halozyme an upfront fee and potential milestone payments, emphasizing the growing need for flexible treatment solutions in managing these chronic conditions. The collaboration is seen as beneficial for improving patient experiences and expanding the application of ENHANZE technology.
Read more →HALOHalozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Halozyme and Skye Bioscience have entered a global collaboration to evaluate nimacimab co-formulated with ENHANZE for obesity treatment. This agreement allows Skye to utilize Halozyme's drug delivery technology to explore higher doses of nimacimab via subcutaneous administration. Skye plans to start a Phase 2b clinical trial in mid-2026 to assess this combination therapy.
Read more →HALOU.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug...
Halozyme Therapeutics announced that Johnson & Johnson's RYBREVANT FASPRO, co-formulated with ENHANZE, has received FDA approval for treating advanced EGFR-mutated non-small cell lung cancer. This new formulation is notable for being the first subcutaneously administered targeted therapy for this patient population, significantly reducing administration time and related reactions compared to intravenous options. The approval is seen as a significant advancement in patient care and healthcare efficiency due to the benefits of the ENHANZE delivery technology.
Read more →HALOJim Lang Elected to Halozyme's Board of Directors
Halozyme Therapeutics has elected Jim Lang to its Board of Directors, bringing over 30 years of leadership experience in healthcare and life sciences. Lang's previous roles include CEO of EVERSANA and Decision Resources Group, where he drove significant growth through acquisitions. His expertise is anticipated to enhance Halozyme's growth strategy and stakeholder value.
Read more →HALOHalozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
Halozyme Therapeutics has won a preliminary injunction in Germany against Merck's Keytruda SC, citing infringement of its MDASE patent. The Munich Regional Court found that Merck must halt its launch activities for Keytruda SC in Germany. Despite this, patients can still access the IV formulation of Keytruda. Halozyme is prepared to defend its patent rights vigorously.
Read more →HALOHalozyme to Participate in the 8th Annual Evercore Healthcare Conference
Halozyme Therapeutics, Inc. will participate in the 8th Annual Evercore Healthcare Conference, with CEO Dr. Helen Torley presenting on December 2. The event will include investor meetings and a live audio webcast. Halozyme is known for its ENHANZE® drug delivery technology and is developing new innovations to enhance patient treatment experiences.
Read more →HALOHalozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Halozyme Therapeutics has successfully acquired Elektrofi, enhancing its drug delivery capabilities with the innovative Hypercon technology. This acquisition is expected to generate royalty revenues starting in 2030 and support clinical development of new products. The deal is valued at up to $900 million, including milestone payments, and aims to improve patient experiences with biologic therapies.
Read more →HALOMerus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab Merus N.V. (Nasdaq: MRUS) ( Merus ), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates...
Merus N.V. and Halozyme Therapeutics have entered a global collaboration to develop a subcutaneous formulation of petosemtamab, a bispecific antibody for treating solid tumors. Merus will utilize Halozyme's ENHANZE drug delivery technology, with the potential for future royalties based on sales. Both companies express optimism about the treatment's potential to improve patient outcomes in head and neck cancer and possibly other indications. Halozyme's history of successful partnerships further supports this initiative.
Read more →HALOFDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
Halozyme Therapeutics announced FDA approval for DARZALEX Faspro as a treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM). This marks the first approved therapy for HR-SMM, allowing for earlier intervention before the disease progresses. The approval is based on the AQUILA study, which demonstrated the efficacy of DARZALEX Faspro compared to standard monitoring.
Read more →HALOHalozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Halozyme Therapeutics has announced the pricing of $650 million in convertible senior notes due in 2031 and 2032. The offering is expected to generate approximately $1.274 billion in net proceeds, which will be used for various corporate purposes, including repurchasing existing convertible notes. The company has also engaged in capped call transactions to mitigate potential dilution of its common stock.
Read more →HALOHalozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 SAN DIEGO, CA (
Halozyme Therapeutics, Inc. has priced a private offering of $650 million in convertible senior notes, comprising two tranches due in 2031 and 2032. The offering, aimed at qualified institutional buyers, allows for initial conversion rates linked to the company's stock price, presenting a premium opportunity for investors. The proceeds will primarily fund capped call transactions and repurchase existing convertible notes. The company anticipates closing the offering on November 12, 2025, pending customary conditions.
Read more →HALOHalozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), today announced that it intends to offer, subject to market conditions and...
Halozyme Therapeutics, Inc. has announced a proposed offering of $650 million in convertible senior notes due in 2031 and 2032. This offering aims to attract qualified institutional buyers and includes an additional option for purchasers to buy up to $200 million more in notes. Proceeds from the offering will fund capped call transactions, repurchase existing convertible notes, and cover general corporate needs, including capital expenditures and potential acquisitions. The company anticipates that certain market activities could affect the price of its common stock and the convertible notes.
Read more →HALOHALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
Halozyme Therapeutics reported strong financial results for Q3 2025, with record revenues and net income. The company raised its 2025 financial guidance, projecting significant growth driven by its ENHANZE technology and recent product approvals. Additionally, Halozyme announced a CFO transition plan, signaling ongoing corporate developments.
Read more →HALOHalozyme to Report Third Quarter 2025 Financial and Operating Results
Halozyme Therapeutics, Inc. announced it will release its third quarter 2025 financial results on November 3, 2025. A conference call will follow the release to discuss the results, accessible via pre-registration. The company is known for its ENHANZE® drug delivery technology, which enhances patient experiences by facilitating subcutaneous drug delivery.
Read more →HALOHalozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s Royalty revenue contribution expected to begin as early as 2030 Initial partner targets inc
Halozyme Therapeutics has announced its acquisition of Elektrofi, a company specializing in innovative drug delivery technology. The deal involves an upfront payment of $750 million, with potential milestone payments. This acquisition is expected to support Halozyme's long-term growth, with projected royalty revenue beginning in 2030. Elektrofi's Hypercon technology aims to enhance biologic therapy delivery through higher concentrations, benefiting both patients and healthcare providers in terms of convenience and effectiveness.
Read more →HALOHalozyme to Participate at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui,...
Halozyme Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. Dr. Helen Torley and Tram Bui will host investor meetings and present insights into the company's operations and innovations. Halozyme specializes in drug delivery technologies and has achieved significant success in improving patient experiences with its ENHANZE technology, which has been utilized globally. The company aims to further its outreach and collaboration within the biopharmaceutical sector.
Read more →HALOHALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
Halozyme Therapeutics reported strong second quarter results for 2025, with total revenue increasing by 41% year-over-year to $326 million. The company also raised its financial guidance for the year, projecting total revenue between $1,275 and $1,355 million. Key growth drivers included a 65% increase in royalty revenue and notable approvals for several therapies. The company completed a $250 million share repurchase as part of its capital allocation strategy.
Read more →HALOEuropean Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received...
Halozyme Therapeutics, Inc. announced that the European Commission has approved DARZALEX Faspro, which utilizes Halozyme's ENHANZE drug delivery technology, for treating adult patients with smouldering multiple myeloma at high risk of progression. This approval marks a critical advancement in early intervention, encouraging proactive treatment rather than merely monitoring the disease. Supported by data from the Phase 3 AQUILA study, this new indication offers hope for improving patient outcomes in this complex blood disorder.
Read more →HALOHalozyme to Report Second Quarter 2025 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its second quarter 2025 financial and operating results on...
Halozyme Therapeutics, Inc. announced that it will release its second quarter 2025 financial and operating results on August 5, 2025. A conference call will be held the same day to discuss these results. The company is known for its ENHANZE® drug delivery technology and its commercial proprietary products, Hylenex® and XYOSTED®. Halozyme is headquartered in San Diego, CA, and has expanded its reach to numerous global markets with its innovative biopharmaceutical solutions.
Read more →HALOHalozyme Therapeutics Added to Russell 1000® Index Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective...
Halozyme Therapeutics, Inc. has been added to the Russell 1000 Index, effective June 27, 2025. This inclusion highlights Halozyme's significant market presence and reflects its leadership in subcutaneous drug delivery technology. CEO Dr. Helen Torley stated that this milestone will enhance the company's visibility and support its strategy for sustainable growth. Halozyme is well-regarded for its innovative ENHANZE technology and has partnered with several major pharmaceutical companies.
Read more →HALOHalozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg...
Halozyme Therapeutics announced that Argonx received European Commission approval for VYVGART® 1000mg, a subcutaneous injection for CIDP. The approval makes VYVGART the first targeted IgG Fc-antibody fragment for this condition in over three decades. With the EC's validation across the EU and select countries, Halozyme anticipates enhanced market access and growth opportunities through its ENHANZE® drug delivery technology. This development underscores a strong partnership with argenx in advancing treatment options for patients.
Read more →HALOHalozyme to Participate at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to ...
Halozyme Therapeutics, Inc. has announced that Dr. Helen Torley will represent the company at upcoming investor conferences, including a Virtual Conference on May 29, 2025, and the Goldman Sachs Global Healthcare Conference on June 9, 2025. At these events, Halozyme will engage in 1x1 meetings and a fireside chat to discuss its advancements and innovations. The company's ENHANZE® technology has significantly improved the delivery of injections and is used by major pharmaceutical partners. This participation highlights Halozyme's commitment to connecting with investors and stakeholders in the biopharmaceutical industry.
Read more →HALOHalozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new...
Halozyme Therapeutics announced that the European Commission has approved a subcutaneous formulation of Opdivo (nivolumab), developed with Halozyme's ENHANZE technology, for multiple solid tumor indications. This makes Opdivo the first PD-1 inhibitor approved for subcutaneous use in the European Union. The approval allows for both monotherapy and combination therapy options, improving treatment convenience for patients. Halozyme anticipates further growth opportunities in 2025 with additional expected approvals.
Read more →HALOHALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to
Halozyme Therapeutics reported strong financial results for Q1 2025, with total revenue increasing 35% year-over-year to $265 million and net income rising 54% to $118 million. The company announced a new $250 million share repurchase and raised its 2025 financial guidance. Significant growth opportunities are anticipated from its expanding portfolio and pipeline, despite recent legal challenges involving a patent infringement lawsuit against Merck. The positive momentum reflects strong performance from existing products and promising new launches.
Read more →HALOHalozyme to Participate in the BofA Securities 2025 Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, will present...
Halozyme Therapeutics, Inc. announced that its CEO, Dr. Helen Torley, will present at the BofA Securities 2025 Healthcare Conference on May 13. The company is known for its ENHANZE drug delivery technology, which enhances patient outcomes by facilitating subcutaneous drug delivery. Halozyme has successfully collaborated with numerous major pharmaceutical firms and has positively impacted over one million patients. A live audio webcast will be available for those unable to attend the event in person.
Read more →HALOHalozyme to Report First Quarter 2025 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its first quarter 2025 financial and operating results on...
Halozyme Therapeutics, Inc. announced it will release its first quarter 2025 financial and operating results on May 6, 2025, after market close. A conference call will be held the same day to discuss these results, accessible via live pre-registration and live webcast. The company, known for its ENHANZE® drug delivery technology, has partnered with leading firms in the biopharmaceutical industry and has reached one million patients globally with its products.
Read more →HALOHalozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal...
Halozyme Therapeutics has announced that argenx received a positive opinion from the CHMP for VYVGART (efgartigimod alfa) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The recommendation signals a step closer to EU approval for a groundbreaking therapy that can be administered via subcutaneous injection. VYVGART represents a novel mechanism of action for CIDP treatment, marking a significant advancement in therapeutic options for this condition. The positive opinion is supported by results from the ADHERE clinical trial, the largest study of CIDP patients to date.
Read more →HALOHalozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug...
Halozyme Therapeutics has filed a patent infringement lawsuit against Merck, alleging that its subcutaneous formulation of Keytruda violates Halozyme's patented MDASE technology. The lawsuit was initiated in response to Merck's intention to launch SC Keytruda in 2025 without securing a commercial license from Halozyme. Halozyme is seeking damages and injunctive relief to halt Merck's plans, emphasizing the importance of its innovative technology for patient drug delivery. The patents in question were developed through extensive research over the past several years, and Halozyme asserts that Merck has knowingly infringed on these patents.
Read more →HALOHalozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of...
Halozyme Therapeutics announced that argenx has received FDA approval for the VYVGART Hytrulo prefilled syringe, which allows for self-injection in patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The prefilled syringe enables a quicker administration process and provides more treatment independence for patients. The approval is based on extensive bioequivalence studies and previous successful clinical trials. This development marks a significant step forward in providing more convenient treatment options for these patient groups.
Read more →HALO▲ +5.4%on this newsshared move
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received...
Halozyme Therapeutics announced that the European Commission has approved the subcutaneous formulation of DARZALEX (daratumumab), administered with ENHANZE technology, for adult patients with newly diagnosed multiple myeloma. This approval allows patients to receive treatment with a combination of daratumumab, bortezomib, lenalidomide, and dexamethasone without the need for intravenous infusions. The decision is based on positive outcomes from the Phase 3 PERSEUS study, bolstering DARZALEX's role in frontline therapy for this condition.
Read more →HALOEuropean Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received...
Halozyme Therapeutics has announced that the European Commission has approved the subcutaneous formulation of RYBREVANT® (amivantamab) for the treatment of advanced non-small cell lung cancer (NSCLC) with particular EGFR mutations. The approval supports a combination treatment with LAZCLUZE® and also allows for amivantamab as monotherapy for specific mutations after platinum-based therapy failure. This marks an important milestone for Halozyme, indicating continued progress in its ENHANZE® drug delivery technology development.
Read more →HALOHalozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received a positive opinion from the Committee for...
Halozyme Therapeutics announced that Bristol Myers Squibb has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the subcutaneous formulation of Opdivo (nivolumab). This formulation, developed with Halozyme's ENHANZE technology, is recommended for treatment across multiple solid tumor indications. The opinion is based on promising results from the Phase 3 CheckMate -67T trial, and the subcutaneous delivery method aims to enhance patient convenience and reduce burdens on healthcare resources. Previous U.S. approval of the formulation occurred in December 2024.
Read more →HALOHalozyme to Participate in the TD Cowen 45th Annual Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, will present...
Halozyme Therapeutics, Inc. announced that Dr. Helen Torley, the CEO, will present at the TD Cowen 45th Annual Healthcare Conference on March 5. The company is known for its ENHANZE® drug delivery technology, which enhances patient experiences by facilitating rapid subcutaneous delivery of medications. With over a million patient interactions through its technology, Halozyme continues to collaborate with major pharmaceutical companies to advance drug development and delivery solutions. Audio webcasts of the presentation will be available live and as replays afterward.
Read more →HALOHALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE of $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA and NON-GAAP DILUTED EPS Fourth Quarter Total Revenue Increased 30% YOY to $298 mil
Halozyme Therapeutics reported significant financial results for the full year of 2024, achieving record revenue of $1.015 billion and exceeding its financial guidance across several metrics. Fourth quarter revenue increased by 30% year-over-year, along with substantial gains in net income and adjusted EBITDA. The company also announced positive developments in regulatory approvals and its 2025 financial guidance, suggesting a robust outlook driven by its ENHANZE technology and key product growth.
Read more →HALOHalozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its fourth quarter and full year 2024 financial and operating ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced the release of its fourth quarter and full year 2024 financial results on February 18, 2025. The company will hold a conference call to discuss these results, which can be accessed via pre-registration. Halozyme is known for its ENHANZE® drug delivery technology and has partnered with numerous leading pharmaceutical companies to enhance patient outcomes.
Read more →HALOCHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a...
Halozyme Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) provided a positive opinion for a subcutaneous formulation of RYBREVANT (amivantamab). This formulation, in combination with lazertinib, is aimed at treating adult patients with advanced non-small cell lung cancer who have specific EGFR mutations. The endorsement is backed by data from the Phase 3 PALOMA-3 study, highlighting benefits such as reduced treatment burden with quicker administration times and fewer infusion-related reactions.
Read more →HALO▲ +5%on this news
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance
Halozyme Therapeutics has reiterated its financial guidance for 2024 while raising expectations for 2025 and beyond. The company projects total revenue for 2025 between $1,150 million and $1,225 million, representing growth of 16% to 23% from 2024. The update is driven by strong growth in royalties and product sales, particularly for VYVGART Hytrulo, along with new product launches. Additionally, Halozyme has initiated a $250 million accelerated share repurchase program.
Read more →HALO▲ +5.8%on this newsshared move
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at...
Halozyme Therapeutics, Inc. has announced an upcoming Investor Conference Call scheduled for January 8, 2025. During this call, the company's executives will present preliminary unaudited financial results for the year 2024 along with updated financial guidance for 2025 and beyond. Halozyme is recognized for its innovative ENHANZE® drug delivery technology, which enhances patient experiences by facilitating the subcutaneous delivery of medications. The company continues to collaborate with numerous major pharmaceutical firms in the industry.
Read more →HALOHalozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion...
Halozyme Therapeutics has announced that Takeda received regulatory approval for HYQVIA, an immune globulin therapy, in Japan for patients with agammaglobulinemia or hypogammaglobulinemia. This marks the first plasma-derived subcutaneous immunoglobulin treatment available in the country, allowing for less frequent dosing compared to traditional methods. The approval was based on pivotal Phase 3 clinical trial data demonstrating safety and efficacy in the target patient population. The innovative ENHANZE technology used in HYQVIA improves drug delivery and administration flexibility, which may enhance the treatment experience for patients.
Read more →HALOHalozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is...
Halozyme Therapeutics announced that argenx's VYDURA, utilizing the ENHANZE® drug delivery technology, has been granted regulatory approval in Japan for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This approval allows for a once-weekly subcutaneous injection that can be self-administered, marking a significant advancement in treatment options for CIDP patients. The efficacy of VYDURA was demonstrated in the ADHERE Study, which showed notable clinical improvements in 69% of participants. The approval enhances treatment flexibility not only for CIDP but also for generalized myasthenia gravis.
Read more →HALOHalozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA)...
Halozyme Therapeutics has announced the FDA approval of Bristol Myers Squibb's Opdivo Qvantig, marking it as the first subcutaneous PD-1 inhibitor. The treatment, which utilizes Halozyme's ENHANZE technology, allows for quicker administration, taking only 3 to 5 minutes compared to IV Opdivo's 30 minutes. Clinical trial results indicated comparable efficacy and safety profiles between Opdivo Qvantig and its intravenous counterpart. However, the approval also highlighted significant adverse reactions, including serious side effects in a notable percentage of patients.
Read more →HALOHalozyme to Present at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that members of the executive leadership team are scheduled to present and...
Halozyme Therapeutics, Inc. has announced that its executive leadership team will present at two upcoming investor conferences on December 4, 2024. The presentations will take place at the Piper Sandler 36th Annual Healthcare Conference in New York and the 7th Annual Evercore ISI HealthCONx Conference in Miami. These sessions emphasize Halozyme's commitment to engaging with investors and showcase its innovations in biopharmaceutical technology aimed at enhancing patient outcomes.
Read more →HALO▲ +7.2%on this newsshared move
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ) today announced it has withdrawn its non-binding proposal to acquire Evotec...
Halozyme Therapeutics has withdrawn its non-binding acquisition proposal for Evotec after the latter showed no interest in engaging in discussions about the potential merger. Despite the setback, Halozyme's CEO expressed confidence in the company's future, highlighting their robust growth strategy and revenue targets for 2024. Halozyme aims to advance its ENHANZE drug delivery technology and continue providing value to its stakeholders, with an optimistic outlook for product approvals and royalty revenues in the coming years.
Read more →HALO▼ -6.7%on this news
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ) today provided an update on its non-binding proposal to acquire Evotec SE...
Halozyme Therapeutics has updated investors on its non-binding proposal to acquire Evotec SE for €11.00 per share, valuing Evotec at €2.0 billion. This acquisition aims to create a leading global pharma services company, diversifying Halozyme's business and enhancing its revenue potential. The all-cash deal would be funded through existing cash reserves and debt, aiming for a pro forma net leverage of less than 2x within two years post-close. This strategic move highlights Halozyme's intention to extend its capabilities in drug discovery, development, and manufacturing.
Read more →HALO▼ -7.9%on this news· ran to -24% by day 3shared move
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ) confirmed it has submitted a non-binding proposal to the Management Board...
Halozyme Therapeutics (NASDAQ: HALO) has proposed a non-binding offer to acquire Evotec for €11.00 per share, valuing Evotec at €2.0 billion. The offer, which represents a substantial premium to Evotec's recent share price, aims to create a global services firm with enhanced capabilities and an extensive pipeline. Halozyme's CEO highlighted the potential for improved patient outcomes through innovation and the strength of their combined technologies. The transaction is not contingent on financing, supported by Halozyme's robust financial position.
Read more →HALOHALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and A
Halozyme Therapeutics, Inc. reported strong financial results for Q3 2024, with total revenue up 34% YoY to $290 million and net income increased by 67% to $137 million. The company raised its financial guidance for 2024, expecting total revenue to reach between $970 and $1,020 million. The growth is largely attributed to increased royalty revenue and successful partnerships enhancing their ENHANZE drug delivery technology. The company's leadership highlighted significant operational momentum and advancements in their product pipeline as key drivers for future success.
Read more →HALOHALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision by the Opposition Division of the European Patent Office...
Halozyme Therapeutics, Inc. provided an update on the status of its co-formulation patent hearing in Europe, indicating that there will be no impact on U.S. or European royalty revenues from its licensed products, including DARZALEX FASPRO. The company reiterated its 2024 royalty revenue guidance of between $520 and $555 million, with expectations to exceed $1 billion in revenues by 2027. Additionally, a conference call regarding further insights is scheduled for October 24.
Read more →HALOHalozyme to Report Third Quarter 2024 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its third quarter 2024 financial and operating results on...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will announce its third quarter 2024 financial and operating results on October 31, 2024, after trading closes. A conference call will follow at 1:30 p.m. PT, where executives will discuss the results. The company is known for its ENHANZE® drug delivery technology that enhances subcutaneous drug administration, benefiting patient experiences. Halozyme is actively collaborating with leading biopharma firms to further its reach in the market.
Read more →HALOHalozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE® Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and license...
Halozyme Therapeutics has expanded its global collaboration with argenx by adding four new targets for its ENHANZE® drug delivery technology, bringing the total to six. As part of this agreement, Halozyme will receive an upfront payment of $30 million and potential milestone payments amounting to $85 million per target. The ENHANZE® technology, which aids in the rapid subcutaneous delivery of drugs, has shown significant success in enhancing patient experiences. This partnership aims to enhance argenx's immunology pipeline, supporting the development of therapies for autoimmune diseases.
Read more →HALOHalozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for...
Halozyme Therapeutics has announced the FDA approval of Roche's OCREVUS ZUNOVO, a new subcutaneous formulation for treating relapsing and primary progressive multiple sclerosis. This innovative product allows for an approximately 10-minute injection, providing greater treatment flexibility. Approval was based on positive results from the Phase III OCARINA II trial, which showed comparable efficacy to existing intravenous formulations. The subcutaneous injection method is expected to improve the patient treatment experience significantly.
Read more →HALOHalozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for...
Halozyme Therapeutics announced that Roche received FDA approval for Tecentriq Hybreza, a subcutaneous formulation of atezolizumab utilizing Halozyme's ENHANZE drug delivery technology. This marks the first subcutaneous anti-PD-(L)1 cancer immunotherapy, allowing for faster administration of treatment. The approval covers all adult indications approved for intravenous Tecentriq, including various cancers. The FDA's decision is based on data from Roche's Phase IB/III study, which confirmed the product's safety and efficacy.
Read more →HALOHalozyme to Present at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui,...
Halozyme Therapeutics, Inc. announced that Dr. Helen Torley and Tram Bui will present at several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. These events will feature various presentation formats, such as fireside chats and one-on-one meetings to engage investors. The company highlights its ENHANZE® drug delivery technology, which aims to enhance patient experiences and outcomes. Live webcasts will be accessible for more extensive audience participation.
Read more →HALOHALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue of $231 million Net Income of $93 million Adjusted EBITDA of $137 million GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.91 1 R
Halozyme Therapeutics reported robust financial results for the second quarter of 2024, with a total revenue of $231 million and a net income of $93 million. The company attributed its performance to a 12% year-over-year increase in royalty revenue and reiterated its financial guidance for the full year, projecting revenue growth of 13% to 22%. Recent partner approvals for treatments like Ocrevus SC and VYVGART Hytrulo underline the ongoing success of its ENHANZE platform. Halozyme aims to expand its product offerings further, with a clear pipeline leading to multiple expected approvals by 2025.
Read more →HALOHalozyme to Report Second Quarter 2024 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its second quarter 2024 financial and operating results on...
Halozyme Therapeutics, Inc. has announced that it will release its second quarter 2024 financial and operating results on August 6, 2024, after the market closes. A conference call for discussion of these results will occur the same day. The company highlighted its ENHANZE technology, which facilitates subcutaneous drug delivery and benefits a sizable patient population. Halozyme's products and partnerships with major biopharmaceutical firms underline its position in the industry.
Read more →HALOHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Roche received European Commission (EC) marketing authorization of...
Halozyme Therapeutics announced that Roche received European Commission marketing authorization for OCREVUS SC, a subcutaneous injection for relapsing and primary progressive multiple sclerosis. This new formulation allows for a quicker 10-minute administration, maintaining the same twice-yearly schedule as the intravenous version, thereby increasing patient accessibility. The approval is backed by data from the Phase III OCARINA II trial, which demonstrated that the subcutaneous version has comparable efficacy and safety profiles to the intravenous formulation.
Read more →HALOHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for...
Halozyme Therapeutics announced that argenx received FDA approval for VYVGART® Hytrulo in treating chronic inflammatory demyelinating polyneuropathy (CIDP). This treatment, utilizing Halozyme's ENHANZE® technology, is the first novel mechanism for CIDP in 30 years and allows for a convenient subcutaneous injection. The FDA approval comes after positive results from the ADHERE study, where a majority of patients showed clinical improvement. This marks the second FDA-approved indication for VYVGART® Hytrulo.
Read more →HALO▲ +12.7%on this news
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that the Company is raising its full year 2024 financial guidance and...
Halozyme Therapeutics, Inc. has announced an increase in its full year 2024 financial guidance due to the grant of European Patent No. 4269578 for its ENHANZE drug delivery platform. The patent will help sustain the royalty rate for sales of DARZALEX SC in validated European countries until its expiration in 2029. With this positive development, Halozyme's total revenue guidance has been adjusted upwards to between $935 and $1,015 million. The company will provide more details during an investor presentation following this announcement.
Read more →HALOHalozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20...
Halozyme Therapeutics, Inc. has announced the grant of European Patent No. 4269578, which covers its ENHANZE® drug delivery technology product, rHuPH20. The patent will be validated in 37 European countries and is set to expire on March 6, 2029. This issuance allows Halozyme to maintain current royalty rates for DARZALEX® SC, thereby securing its financial outlook. Additionally, the patent reinforces Halozyme's existing collaborations and market position in drug delivery solutions.
Read more →HALOHalozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, will present...
Halozyme Therapeutics, Inc. has announced that Dr. Helen Torley will present at the Goldman Sachs 45th Annual Global Healthcare Conference, taking place on June 11, 2024. The presentation will be accessible via a live audio webcast on the company's website, with replays available for 90 days post-event. Halozyme is recognized for its ENHANZE® drug delivery technology, which has enhanced the treatment experience for over 800,000 patients across global markets. The company continues to develop and commercialize innovative biopharmaceutical solutions.
Read more →HALOHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE® Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act...
Halozyme Therapeutics has announced that the U.S. FDA has updated the Prescription Drug User Fee Act goal date for Bristol Myers Squibb's Biologics License Application related to the subcutaneous formulation of nivolumab co-formulated with ENHANZE. The new goal date is set for December 29, 2024. The application is based on promising results from the Phase 3 CheckMate-67T trial, which demonstrated noninferior pharmacokinetics and safety compared to the intravenous formulation. If approved, this could represent a significant advancement in PD-1 inhibitor administration, improving patient comfort and adherence.
Read more →HALOHalozyme to Participate in Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and...
Halozyme Therapeutics, Inc. has announced that Chief Financial Officer Nicole LaBrosse will present at two upcoming investor conferences. The first is the Citizens JMP Life Sciences Conference on May 14, 2024, in New York, involving a fireside chat and one-on-one meetings. The second event is the Benchmark 2024 Healthcare House Call Virtual Conference, scheduled for May 21 and 22, 2024. The company continues to advance its ENHANZE® drug delivery technology, which has been successfully used in various commercial products.
Read more →HALOHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS Revenue Increased 21% YOY to $196 million Net Income of $77 million Adjusted EBITDA of $116 million GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS o
Halozyme Therapeutics reported a strong financial performance for the first quarter of 2024, with a 21% increase in revenue to $196 million and net income of $77 million. The company reiterated its financial guidance for the year, anticipating total revenue of $915 to $985 million, alongside an adjusted EBITDA growth of 26% to 37%. Notably, Halozyme also announced a $750 million share repurchase program, emphasizing its commitment to enhancing shareholder value. The positive outcomes from partnerships and product approvals further contribute to the optimistic outlook for the company.
Read more →HALOMahesh Krishnan Elected to Halozyme's Board of Directors Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan ...
Halozyme Therapeutics, Inc. has announced the election of Dr. Mahesh Krishnan to its Board of Directors. Dr. Krishnan, who has over 20 years of experience in biotechnology and health services, is expected to contribute to the company's growth through his expertise. He has previously held significant roles in organizations such as DaVita and Amgen, focusing on strategic partnerships and medical policies. His election aligns with Halozyme's goal to advance disruptive drug delivery technologies aimed at improving patient outcomes.
Read more →HALOHalozyme to Report First Quarter 2024 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its first quarter 2024 financial and operating results on...
Halozyme Therapeutics, Inc. has announced the date for its first quarter 2024 financial and operating results, which will be released on May 7, 2024, after market close. Following the release, the company will host a conference call to discuss the results. Halozyme is known for its ENHANZE® drug delivery technology and has made a significant impact on patient care with its products, which have reached over 800,000 patients worldwide.
Read more →HALOHalozyme to Participate in Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to ...
Halozyme Therapeutics, Inc. has announced that Dr. Helen Torley, CEO, will present and host investor meetings at multiple upcoming conferences, including the TD Cowen 44th Annual Healthcare Conference and the Barclays 26th Annual Global Healthcare Conference. These events will feature fireside chats and one-on-one meetings, aimed at promoting the company's innovative ENHANZE® drug delivery technology. Halozyme's technology facilitates subcutaneous delivery of medications, currently benefiting over 800,000 patients globally. The company aims to enhance patient treatment experiences through its partnerships and product offerings.
Read more →HALODocument HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS Reiterating 2024 Financial Guidance Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $53
Halozyme Therapeutics reported strong financial results for Q4 and full-year 2023, with total revenue increasing by 27% to $230 million in Q4. The company reiterated its financial guidance for 2024, anticipating total revenue between $915 million and $985 million, representing year-over-year growth of 10% to 19%. Additionally, Halozyme announced a new $750 million share repurchase program, highlighting confidence in ongoing growth. The report includes several positive developments, such as multiple FDA approvals and successful product launches that may drive future revenue.
Read more →HALOHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million,...
Halozyme Therapeutics (NASDAQ: HALO) reported strong financial results for the fourth quarter and full year of 2023, with total revenue increasing by 26% year-over-year to $829 million. The company reiterated its financial guidance for 2024, expecting revenues of $915 to $985 million, driven by growth from new product approvals and successful collaborations. Positive developments in clinical partnerships, such as the approval of VYVGART Hytrulo, contribute to a promising outlook. Additionally, a new $750 million share repurchase program signals confidence in the company's sustained growth.
Read more →HALOHalozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its fourth quarter and full year 2023 financial and operating ...
Halozyme Therapeutics, Inc. has announced that it will release its fourth quarter and full year 2023 financial results on February 20, 2024. The company will hold a conference call to discuss these results, available through registration. Halozyme continues to focus on improving patient experiences through its ENHANZE technology and has partnered with various leading pharmaceutical firms. The company has a significant presence in the biopharmaceutical industry, with products used in over 100 markets worldwide.
Read more →HALOHalozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune...
Halozyme Therapeutics has announced that the European Commission has approved Takeda's use of HYQVIA, co-formulated with Halozyme's ENHANZE technology, as a maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). This approval allows for treatment in patients of all ages who have stabilized with intravenous immunoglobulin therapy. HYQVIA is also FDA-approved and is notable for being administrable at home after training, thus improving patient experience. The approval also highlights the growing demand for personalized treatment options in the CIDP space.
Read more →HALOHalozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that argenx received approval from Japan's Ministry of Health, Labour and...
Halozyme Therapeutics, Inc. announced that argenx has received approval for VYVDURA® in Japan, a co-formulated injection for generalized myasthenia gravis. The drug is designed for self-administration, enhancing convenience for patients. This approval follows positive outcomes from the Phase 3 ADAPT-SC study, which demonstrated its efficacy compared to IV treatments. VYVDURA® will offer a new treatment option for adult patients who do not respond adequately to traditional therapies.
Read more →HALO▲ +5.6%on this newsshared move
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Takeda received U.S. Food and Drug Administration (FDA) approval for...
Halozyme Therapeutics, Inc. announced that Takeda has received FDA approval for HYQVIA®, co-formulated with Halozyme's ENHANZE® technology, for use as maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This FDA approval expands HYQVIA's previous use, allowing for monthly infusions that can be administered at home or in healthcare settings. This innovative treatment option aims to significantly improve patient outcomes by preventing relapse in neuromuscular disabilities in CIDP patients.
Read more →HALO▲ +5.6%on this newsshared move
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Roche received European Commission (EC) marketing authorization of...
Halozyme Therapeutics announced that Roche has received European Commission approval for Tecentriq SC, the first subcutaneous PD-(L)1 immunotherapy in Europe. This new formulation significantly reduces treatment time to about 7 minutes compared to 30-60 minutes for IV infusion. The approval is based on promising data from the Phase IB/III IMscin001 study, indicating comparable safety and efficacy. This innovation offers an easier administration method, making it possible for healthcare providers to give treatments outside of hospitals, which may improve patient experiences and ease burdens on healthcare systems.
Read more →HALOHalozyme to Host Investor Business Forum and Long-Term Outlook Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that it will host an Investor Business Forum and Long-Term Outlook Call on...
Halozyme Therapeutics, Inc. will host an Investor Business Forum and Long-Term Outlook Call on January 17, 2024. The event will feature CEO Dr. Helen Torley, Chief Legal Officer Mark Snyder, and CFO Nicole LaBrosse, who will discuss the company's patent dynamics related to its ENHANZE® technology. Additionally, Halozyme will provide its 2024 financial guidance and long-term outlook during the call, which will be accessible via webcast.
Read more →HALOHalozyme to Present at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that members of the senior leadership team are scheduled to present and host...
Halozyme Therapeutics, Inc. has announced that its senior leadership team will present at two upcoming investor conferences in late November 2023. The presentations will include a fireside chat led by the CFO at the Piper Sandler Healthcare Conference and another by the CEO at the Evercore ISI HealthCONx Conference. These events will feature discussions on Halozyme's innovative ENHANZE technology, which facilitates drug delivery and enhances patient experience. A live audio webcast will be available on the company’s website for those unable to attend in person.
Read more →HALOHalozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that argenx received European Commission (EC) approval of VYVGART® SC...
Halozyme Therapeutics announced that argenx has received European Commission approval for VYVGART® SC, a treatment for generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody positive. This approval allows for self-administration, which could enhance patient convenience. The approval comes shortly after the treatment received US approval in June 2023 and is based on positive results from the Phase 3 ADAPT-SC study.
Read more →HALOHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted
Halozyme Therapeutics reported its financial results for Q3 2023, showcasing a 15% increase in royalty revenue, bringing it to a record $114.4 million. The company also accelerated a $250 million share repurchase plan and raised its EBITDA guidance for the year. Significant progress was noted in clinical studies and partnerships, although delays in product launches and an impairment charge affected overall performance.
Read more →HALOHalozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals...
Halozyme Therapeutics has entered a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals for the ENHANZE® technology, which will be used to enhance ACU193, a monoclonal antibody targeting Alzheimer's disease. This marks Halozyme's thirteenth collaboration involving ENHANZE, which aims to improve drug delivery for therapeutic treatments. Acumen has reported positive Phase 1 results for ACU193, showing its potential in treating early Alzheimer's disease. The agreement also entails potential upfront and milestone payments, establishing a promising financial outlook for Halozyme.
Read more →HALOHalozyme To Report Third Quarter 2023 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its third quarter 2023 financial and operating results on...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced it will release its third quarter 2023 financial and operating results on November 6, 2023. Following the release, a conference call will take place to discuss the results, which interested parties can access online. The company is noted for its ENHANZE technology that improves patient experiences and has touched over 700,000 lives across various markets. Halozyme also engages in partnerships with leading pharmaceutical companies to enhance drug delivery solutions.
Read more →HALOPositive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Bristol Myers Squibb (BMS) reported positive topline results from the...
Halozyme Therapeutics announced that Bristol Myers Squibb reported positive topline results from the Phase 3 CheckMate-67T trial, which evaluated a subcutaneous formulation of nivolumab for patients with advanced or metastatic clear cell renal cell carcinoma. The trial successfully met its co-primary and key secondary endpoints, indicating the effectiveness of the treatment. Halozyme's ENHANZE technology was utilized for this formulation, offering potential benefits in terms of treatment administration time. BMS plans to share detailed results at a medical meeting and is in discussions with health authorities for regulatory submission.
Read more →HALOHalozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced positive results of a clinical study demonstrating subcutaneous...
Halozyme Therapeutics, Inc. announced positive results from a clinical study demonstrating the successful subcutaneous administration of a 10 mL biologic product using its proprietary high-volume auto-injector in about 30 seconds. All 23 healthy volunteers received the injection successfully, with the study meeting its primary endpoint. This innovative delivery method, enabled by Halozyme's ENHANZE technology, potentially enhances the patient experience by allowing rapid delivery of large volumes of biologics. The technology is now available for clinical use by partners.
Read more →HALOUpdate: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) will present the positive results of a clinical study demonstrating subcutaneous...
Halozyme Therapeutics has reported positive results from a clinical study that demonstrated the successful subcutaneous administration of a 10 mL biologic using its proprietary high-volume auto-injector (HVAI). Conducted on 23 healthy volunteers, the study showed that the biologic was delivered in approximately 30 seconds without adverse effects. This breakthrough technology could significantly enhance patient experiences by facilitating rapid and efficient drug delivery, particularly for therapies that are currently restricted to smaller volumes.
Read more →HALOHalozyme to Present at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to ...
Halozyme Therapeutics, Inc. announced that CEO Dr. Helen Torley will present at several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the H.C. Wainwright Annual Conference. These presentations will include fireside chats and 1x1 meetings aimed at fostering investor relations. The company is known for its ENHANZE® technology, which enhances drug delivery for better patient outcomes. Live audio webcasts of the presentations will be available on the company's website.
Read more →HALOHalozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's...
Halozyme Therapeutics has announced the approval of Roche's Tecentriq® SC in Great Britain, utilizing Halozyme's ENHANZE® drug delivery technology. The new subcutaneous formulation significantly reduces the treatment time to approximately seven minutes, facilitating a more convenient option for patients. Tecentriq® SC will be available for various cancer types including lung, bladder, breast, and liver cancer. The approval is based on clinical data demonstrating comparable efficacy and safety to the intravenous formulation, while the FDA is yet to evaluate this new format for U.S. regulatory approval.
Read more →HALOHALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS Revenue Increased 45% YOY to $221.0 million GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.74 1 Royalty Revenue Increased 31% YOY to Record $
Halozyme Therapeutics reported a strong financial performance for the second quarter of 2023, with a 45% increase in revenue year-over-year, totaling $221 million. Non-GAAP diluted earnings per share rose to $0.74, prompting the company to raise its financial guidance for the year. Significant advancements include the FDA approval of VYVGART Hytrulo and positive clinical trial results for treatments incorporating the ENHANZE technology. Additionally, the company anticipates robust growth driven by upcoming product launches and ongoing partnerships.
Read more →HALOHalozyme To Report Second Quarter 2023 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its second quarter 2023 financial and operating results on...
Halozyme Therapeutics, Inc. announced it will release its financial and operating results for the second quarter of 2023 on August 8, 2023. Following the release, a conference call to discuss these results will be held at 4:30 p.m. ET. The company continues to develop innovative solutions to improve patient experiences, with over 700,000 patients benefiting from its proprietary technology. Halozyme partners with leading pharmaceutical firms, enhancing its market presence.
Read more →HALO▲ +5.4%on this news
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that argenx reported positive topline data from the ADHERE study evaluating...
Halozyme Therapeutics, Inc. announced that argenx reported positive topline data from the ADHERE study of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint, showing a significantly lower risk of relapse compared to placebo. Detailed findings will be presented at an upcoming medical meeting. This success follows a recent approval for VYVGART in generalized myasthenia gravis and suggests promising potential for treating severe autoimmune diseases.
Read more →HALO▲ +5.4%on this newsshared move
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Roche's Phase 3 OCARINA II trial evaluating OCREVUS® (ocrelizumab) with...
Halozyme Therapeutics announced positive results from Roche's Phase 3 OCARINA II trial, which evaluated the subcutaneous formulation of OCREVUS (ocrelizumab) with Halozyme's ENHANZE drug delivery technology. The trial met its primary and secondary endpoints, confirming that the subcutaneous injection is non-inferior to the intravenous formulation. This new delivery method allows patients with multiple sclerosis to receive treatment in just 10 minutes twice a year, potentially improving access to treatment. Roche plans to share detailed results at a medical meeting and will seek regulatory approval globally.
Read more →HALOHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for...
Halozyme Therapeutics announced that argenx received FDA approval for VYVGART® Hytrulo, a subcutaneous injectable for treating generalized myasthenia gravis (gMG) in antibody-positive adults. This approval, based on positive outcomes from the Phase 3 ADAPT-SC study, allows for a more convenient weekly injection regimen, enhancing treatment flexibility for patients. Halozyme's ENHANZE® drug delivery technology is utilized to facilitate this subcutaneous administration, potentially improving patient experiences. The company anticipates further data readouts for additional autoimmune conditions later this year.
Read more →HALOHalozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, will present at ...
Halozyme Therapeutics, Inc. announced that CEO Dr. Helen Torley will present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023. The presentation will focus on the company's innovative ENHANZE technology, which facilitates drug delivery and has improved patient experience. Halozyme has licensed this technology to major pharmaceutical companies and has reached over 700,000 patients globally. The conference presentation is expected to highlight the company's ongoing product development and collaborations in the biopharma industry.
Read more →HALOHALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS Revenue Increased 38% YOY to $162.1 million GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue
Halozyme Therapeutics reported a robust first quarter of 2023, with revenues increasing by 38% year-over-year to $162.1 million, driven primarily by royalty revenue from its products. The company has maintained its financial outlook for 2023, expecting total revenues between $815 million and $845 million. However, there were notable declines in operating income and net income compared to the previous year, raising concerns about rising operational costs. Despite these challenges, the overall growth trajectory remains strong, supported by ongoing collaborations and product launches.
Read more →HALOHalozyme To Report First Quarter 2023 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its first quarter 2023 financial and operating results on...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced the release date for its first quarter 2023 financial and operating results, which will be made public on May 9, 2023. Following the results, a conference call will be held to discuss the outcomes. The company emphasizes its innovative ENHANZE® technology and extensive partnerships that highlight its significant impact on patient care. With a strong commercial portfolio, Halozyme demonstrates commitment to improving treatment experiences for patients.
Read more →HALOHALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPRO and SC through at least 2030 Reiterates 2023 Revenue G
Halozyme Therapeutics provided an update regarding a European Patent Office decision that affects a co-formulation patent for DARZALEX, indicating no expected impact on its royalty revenues through 2030. The company reiterated its revenue guidance for 2023, projecting between $815 million and $845 million, and maintains a strong outlook for its royalty revenue. Despite this, Halozyme expressed disappointment with the decision to revoke a related patent and mentioned potential appeal processes that could affect future operations.
Read more →HALOHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS Fourth Quarter Revenue Increased 78% YOY to $181 million GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share
Halozyme Therapeutics reported strong financial results for Q4 and full year 2022, with revenue increasing 78% to $181 million and a projected revenue growth for 2023 of 23%-28%. Their successful acquisition of Antares Pharma has contributed significantly to these results. However, the company's net income decreased compared to 2021, and cash equivalents dropped considerably. Finally, Halozyme is optimistic about upcoming regulatory approvals for products utilizing its ENHANZE technology.
Read more →HALOHalozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its fourth quarter and full year 2022 financial and operating ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announces it will release its fourth quarter and full year 2022 financial and operating results on February 21, 2023. The release will be followed by a conference call at 4:30 p.m. ET for discussions on the results. Halozyme is known for its ENHANZE® technology, which improves drug delivery and patient outcomes and has been validated through the use of its products across multiple markets.
Read more →HALOHalozyme Appoints Barbara Duncan to its Board of Directors Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan...
Halozyme Therapeutics, Inc. announced the appointment of Barbara Duncan to its Board of Directors. Duncan brings over 25 years of financial leadership in the biopharmaceutical industry, with notable roles at Intercept Pharmaceuticals and DOV Pharmaceutical. The company's president highlighted her expertise as a valuable asset for Halozyme's continued growth and success. Duncan expressed her enthusiasm for joining Halozyme at a pivotal time in its development, particularly concerning its innovative drug delivery technologies.
Read more →HALO▼ -9.2%on this news
HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that it has elected to redeem on March 17, 2023 (the Redemption Date ) all...
Halozyme Therapeutics, Inc. has announced its decision to redeem all outstanding 1.25% convertible senior notes due 2024 on March 17, 2023. Holders of the notes can convert their investment into common stock at a specified conversion rate before the redemption date. The redemption reflects Halozyme's commitment to financial stability and effective management of its obligations. The company continues to develop innovative biopharmaceutical solutions that have positively impacted patient care.
Read more →HALODocument Halozyme Provides 2023 Financial Guidance and Outlook 2023 Total Revenue Guidance of $815 to $845 Million Representing 20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from Royalties Projected to Gr
Halozyme Therapeutics, Inc. provided its financial guidance for 2023, projecting total revenues between $815 million and $845 million, marking a 20% growth from 2022. The company anticipates EBITDA growth of 30%, expecting a range of $415 million to $440 million for the year. Halozyme expects its recurring royalties to grow by 20%, driven by success in products using its ENHANZE technology, including planned commercial launches for SC efgartigimod and SC atezolizumab. The company aims to enhance shareholder value through a significant share repurchase program.
Read more →HALOHalozyme Provides 2023 Financial Guidance and Outlook Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced its 2023 financial guidance and commented on its outlook for the upcoming year....
Halozyme Therapeutics, Inc. announced its 2023 financial guidance, projecting total revenues between $815 million and $845 million, representing over 20% growth from 2022. They predict a significant increase in EBITDA, expecting it to rise by more than 30% to reach between $415 million and $440 million. The company also highlighted the potential for new commercial opportunities with the anticipated launches of SC efgartigimod and SC atezolizumab, strengthening their royalty revenue streams. This announcement follows their record revenue accomplishment of over $655 million in 2022.
Read more →HALOHalozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, will present at ...
Halozyme Therapeutics, Inc. announced that Dr. Helen Torley, its CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The presentation aims to highlight the company's innovative ENHANZE technology, which facilitates drug delivery and enhances patient treatment experiences. Established partnerships with leading pharmaceutical companies underscore Halozyme's commercial reach and success. A live audio webcast of the presentation will be available for interested stakeholders.
Read more →HALO▲ +8.5%on this news
Halozyme to Participate in Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that members of its management team are scheduled to present and host...
SAN DIEGO , Nov. 9, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that members of its management team are scheduled to present and host investor meetings at the following investor conferences: Live audio webcasts of the Piper Sandl
Read more →HALOHALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS Third Quarter Revenue Increased 80% YOY to $209 million, with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.74
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS Third Quarter Revenue Increased 80% YOY to $209 million, with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.741 Record Third Quarter Royalty Revenue Increased 70% YOY to
Read more →HALOHalozyme to Report Third Quarter 2022 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its third quarter 2022 financial and operating results on...
SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced it will release its third quarter 2022 financial and operating results on Tuesday, November 8, 2022 , following the close of trading. Halozyme will host a conferenc
Read more →HALOHalozyme to Participate in the 2022 Wells Fargo Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to ...
SAN DIEGO , Sept. 1, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, is scheduled to present and host investor meetings at the 2022 Wells Fargo Healthcare Conference being
Read more →HALOHalozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous delivery and...
The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering SAN DIEGO , Aug. 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme" or the "Company"), a leader in converting IV biolog
Read more →HALOHalozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous delivery, today...
SAN DIEGO , Aug. 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $625.0 million aggregate principal amount of convertible senior notes
Read more →HALOHalozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028 SAN DIEGO, CA (
Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028 SAN DIEGO, CA (August 15, 2022) Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subc
Read more →HALOHALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022 Second
HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022 Second Quarter Revenue Increased 12% YOY to $152.4 million, with
Read more →HALOPositive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Roche's Phase III IMscin001 study evaluating a subcutaneous (SC)...
Subcutaneous formulation with ENHANZE ® reduced treatment time to 3-8 minutes compared to 30-60 minutes for standard intravenous infusion SAN DIEGO , Aug. 2, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that Roche's Phase III IMsc
Read more →HALOHalozyme to Report Second Quarter 2022 Financial and Operating Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced it will release its second quarter 2022 financial and operating results on...
SAN DIEGO , July 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced it will release its second quarter 2022 financial and operating results on Tuesday, August 9, 2022 , following the close of trading. Halozyme will host a conference
Read more →HALOHalozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to ...
SAN DIEGO , June 8, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, is scheduled to present and host investor meetings at the Goldman Sachs 43 rd Annual Global Healthcare
Read more →HALOHalozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral...
SAN DIEGO , June 7, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated
Read more →HALOHalozyme Completes Antares Pharma Acquisition Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced the successful completion of its acquisition of Antares Pharma, Inc....
SAN DIEGO , May 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (" Halozyme ") today announced the successful completion of its acquisition of Antares Pharma, Inc. (" Antares "). The tender offer for all of the outstanding shares of Antares common stock expi
Read more →HALOHalozyme Completes Antares Pharma Acquisition
Halozyme Completes Antares Pharma Acquisition SAN DIEGO, May 24, 2022 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced the successful completion of its acquisition of Antares Pharma, Inc. ( Antares ). The tender offer for all of the outstanding shares of
Read more →HALOHart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements...
SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (" Halozyme ") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the " HSR Act "), applicable to Halozyme's proposed acquisition
Read more →HALOHALOZYME REPORTS FIRST QUARTER 2022 RESULTS First Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47 Record
HALOZYME REPORTS FIRST QUARTER 2022 RESULTS First Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47 Record Quarterly Royalties in the First Quarter of $69.6 million,
Read more →HALOHalozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET /...
SAN DIEGO , May 3, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president, and chief executive officer, will lead the cal
Read more →HALOHALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub,...
SAN DIEGO , April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. (" Purchaser "), a cash tender offer to purchase all outstanding shares of common s
Read more →HALOHalozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Fina
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delive
Read more →HALOHalozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that...
SAN DIEGO , March 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gives exclusive access to Halozyme's ENHANZE ® drug delivery technology, recombinant human
Read more →HALOPositive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that data from argenx's Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod...
- Study met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to intravenous (IV) administration - - Biologics License Application on track to be submitted by argenx to U.S. Food and Drug Administrati
Read more →HALOHalozyme Appoints Moni Miyashita to Board of Directors Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an...
SAN DIEGO , March 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an accomplished executive with over 25 years of global strategic, mergers & acquisitions and busine
Read more →HALOHALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS - Reports Fourth Quarter Revenue of $102.0 million with GAAP Diluted Earnings per Share of $0.46 and Non-GAAP Diluted Earnings per Share of $0.42 - - Reports Ful
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS - Reports Fourth Quarter Revenue of $102.0 million with GAAP Diluted Earnings per Share of $0.46 and Non-GAAP Diluted Earnings per Share of $0.42 - - Reports Full Year 2021 Revenue of $443.3 million with GAAP Diluted Ea
Read more →HALOHALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2021 on Tuesday, February 22 at...
SAN DIEGO , Feb. 9, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the fourth quarter 2021 on Tuesday, February 22 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, wi
Read more →HALOHalozyme Appoints New Chief Financial Officer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief...
SAN DIEGO , Feb. 2, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse will succeed Elaine Sun , who is step
Read more →HALODocument Halozyme Appoints New Chief Financial Officer
Halozyme Appoints New Chief Financial Officer SAN DIEGO, February 2, 2022 - Halozyme Therapeutics, Inc. (NASDAQ HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse wil
Read more →HALOHALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2022 financial guidance and commented on its outlook for the upcoming year. Halozyme had ...
SAN DIEGO , Jan. 10, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today introduced 2022 financial guidance and commented on its outlook for the upcoming year. "Halozyme had another strong year of financial performance in 2021 with record revenues and profitab
Read more →HALODocument HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK - 2022 Revenue Guidance of $530 to $560 Million Representing 23-26% Growth over Expected 2021 Revenue - - 2022 Recurring Revenue from Royalties Projected to
HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK - 2022 Revenue Guidance of $530 to $560 Million Representing 23-26% Growth over Expected 2021 Revenue - - 2022 Recurring Revenue from Royalties Projected to Grow by Approximately 50% over Record Royalties in 2021 to Approxim
Read more →HALOHalozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at...
SAN DIEGO , Jan. 4, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will present virtually at the 40 th Annual J.P. Morgan Health Care Conference on Monday, January 10, 2022 at 7:30 a.
Read more →HALODocument
HALOZYME APPOINTS NEW GENERAL COUNSEL SAN DIEGO, December 13, 2021 - Halozyme Therapeutics, Inc. (NASDAQ HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3, 2022.
Read more →HALOHALOZYME APPOINTS NEW GENERAL COUNSEL Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief...
SAN DIEGO , Dec. 13, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3 , 2022. Mr. Snyder will succeed
Read more →HALOHALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its Board of Directors has approved a new share repurchase program effective...
SAN DIEGO , Dec. 9, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that its Board of Directors has approved a new share repurchase program effective immediately, which authorizes the Company to purchase up to $750 million of the Company's outstan
Read more →HALOHalozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval...
SAN DIEGO , Dec. 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with Kyprolis ®
Read more →HALOHalozyme to Present at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences: 33rd Annual Piper Sandler...
SAN DIEGO , Nov. 18, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it will participate at the following investor conferences: A direct link to the presentations can be accessed through the "Investors" section of www.halozyme.com , and a re
Read more →HALOHALOZYME REPORTS THIRD QUARTER 2021 RESULTS - Record Quarterly Royalties in the Third Quarter of $58.6 million Representing 145% Growth over Third Quarter 2020 - - Third Quarter Revenue of $115.8 million with GAAP Dilute
HALOZYME REPORTS THIRD QUARTER 2021 RESULTS - Record Quarterly Royalties in the Third Quarter of $58.6 million Representing 145% Growth over Third Quarter 2020 - - Third Quarter Revenue of $115.8 million with GAAP Diluted Earnings per Share of $1.48 and Non-GAAP Diluted Earning
Read more →HALOHalozyme Reports Third Quarter 2021 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2021 and provided an update on...
SAN DIEGO , Nov. 2, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the third quarter ended September 30, 2021 and provided an update on its recent corporate activities and outlook. "Our strong 2021 performance continued in t
Read more →HALOHalozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2021 on November 2 at 4:30 p.m. ET ...
SAN DIEGO , Oct. 19, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the third quarter 2021 on November 2 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will lead th
Read more →HALOHalozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will present at the...
SAN DIEGO , Sept. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Elaine Sun , senior vice president and chief financial officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 1:20
Read more →HALOHalozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present at the Wells...
SAN DIEGO , Aug. 26, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will present at the Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 10:40 a.m. East
Read more →HALOHALOZYME REPORTS SECOND QUARTER 2021 RESULTS - Raising 2021 Revenue Guidance to $425-$445 Million from $375-$395 Million, GAAP Earnings Per Share Guidance to $1.55-$1.70 from $1.25-$1.40 and Non-GAAP Earnings per Share G
HALOZYME REPORTS SECOND QUARTER 2021 RESULTS - Raising 2021 Revenue Guidance to $425-$445 Million from $375-$395 Million, GAAP Earnings Per Share Guidance to $1.55-$1.70 from $1.25-$1.40 and Non-GAAP Earnings per Share Guidance to $1.85-$2.00 from $1.55-$1.70- - Second Quarter
Read more →HALOHalozyme Reports Second Quarter 2021 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2021 and provided an update on its...
SAN DIEGO , Aug. 9, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the second quarter ended June 30, 2021 and provided an update on its recent corporate activities and outlook. "Our excellent start to 2021 continued in the s
Read more →HALOHalozyme to Participate in Canaccord Genuity 41st Annual Growth Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will virtually...
SAN DIEGO , July 30, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Elaine Sun , senior vice president and chief financial officer, will virtually represent the company in a fireside chat at the Canaccord Genuity 41 st Annual Growth Conferen
Read more →HALOHalozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2021 on Monday, August 9 at 4:30...
SAN DIEGO , July 27, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the second quarter 2021 on Monday, August 9 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will
Read more →HALOHalozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA)...
SAN DIEGO , July 12, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with pomal
Read more →HALOViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of ultra-long-acting medicines for HIV ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ( GSK ), with Pfizer Inc. and Shionogi Limited as...
LONDON and SAN DIEGO , June 22, 2021 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced a global c
Read more →HALOHalozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of...
SAN DIEGO , June 22, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumum
Read more →HALOHalozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced abstracts and presentations by its collaborators for the 2021 American Society of Clinical ...
SAN DIEGO , June 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced abstracts and presentations by its collaborators for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2021 . Janssen Research &
Read more →HALOHalozyme to Present at Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences: The Goldman Sachs 42nd...
SAN DIEGO , May 28, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it will participate at the following investor conferences: These conferences will be held virtually. Live webcasts of the applicable presentations will be accessible on the
Read more →HALOHalozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE® Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Pharmaceutica N.V. (Janssen) received two positive opinions from the...
SAN DIEGO , May 21, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Janssen Pharmaceutica N.V. (Janssen) received two positive opinions from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reco
Read more →HALOHalozyme Reports First Quarter 2021 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2021 and provided an update on its...
SAN DIEGO , May 10, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the first quarter ended March 31, 2021 and provided an update on its recent corporate activities and outlook. "The first quarter marked a strong start to 202
Read more →HALOHALOZYME REPORTS FIRST QUARTER 2021 RESULTS - First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 - - Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119%
HALOZYME REPORTS FIRST QUARTER 2021 RESULTS - First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 - - Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119% Growth over First Quarter 2020 - - Reiterate 2021 Revenue
Read more →HALOHalozyme to Present at BofA Securities 2021 Virtual Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at...
SAN DIEGO , April 29, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will present virtually at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 12:3
Read more →HALOHalozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m....
SAN DIEGO , April 20, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will le
Read more →HALOHalozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous delivery, today...
SAN DIEGO , Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior note
Read more →HALOHalozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 SAN DIEGO, CA (
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 SAN DIEGO, CA (February 24, 2021) Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous
Read more →HALOHalozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous delivery, today...
SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, $500 millio
Read more →HALOHALOZYME REPORTS FOURTH QUARTER 2020 RESULTS AND FULL YEAR 2020 RESULTS - Reports Fourth Quarter 2020 Revenue of $121.7 million and Earnings Per Share of $0.50 - - Reports Full Year 2020 Revenue of $267.6 million and Ear
HALOZYME REPORTS FOURTH QUARTER 2020 RESULTS AND FULL YEAR 2020 RESULTS - Reports Fourth Quarter 2020 Revenue of $121.7 million and Earnings Per Share of $0.50 - -Reports Full Year 2020 Revenue of $267.6 million and Earnings Per Share of $0.91 - - Successful Launch of DARZALEX
Read more →HALOHalozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2020 on Tuesday, February 23 at...
SAN DIEGO , Feb. 10, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the fourth quarter 2020 on Tuesday, February 23 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, w
Read more →HALOHalozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) has received U.S. Food and Drug Administration (FDA)...
SAN DIEGO , Jan. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Janssen Biotech, Inc. (Janssen) has received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with b
Read more →HALOhalozyme2021_jpmxfi 39th Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO
39th Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO January 13, 2021 1 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation,
Read more →HALOHALOZYME PROVIDES 2021 FINANCIAL GUIDANCE HIGHLIGHTED BY STRONG REVENUE AND EPS GROWTH - 2021 Revenue Guidance of $375 to $395 Million Representing 40%-45% Growth over Expected 2020 Revenue - - 2021 Royalties Projected t
HALOZYME PROVIDES 2021 FINANCIAL GUIDANCE HIGHLIGHTED BY STRONG REVENUE AND EPS GROWTH - 2021 Revenue Guidance of $375 to $395 Million Representing 40%-45% Growth over Expected 2020 Revenue - - 2021 Royalties Projected to Double versus Expected 2020 Royalties - - 2021 EPS Guid
Read more →HALOHalozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at...
SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 12:40
Read more →HALOHalozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo®, a fixed-dose combination of...
SAN DIEGO , Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the European Commission has approved Roche's Phesgo ® , a fixed-dose combination of Perjeta ® (pertuzumab) and Herceptin ® (trastuzumab) with Halozyme's ENHANZE ® technology
Read more →HALOHorizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement...
DUBLIN and SAN DIEGO , Nov. 23, 2020 /PRNewswire/ -- Horizon Therapeutics plc (Nasdaq: HZNP ) and Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE ® drug delivery tec
Read more →HALOHalozyme Raises Full Year 2020 Guidance Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global...
SAN DIEGO , Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon Therapeutics plc. The Company is raising full yea
Read more →HALOHalozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a...
SAN DIEGO , Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will participate in a fireside chat presentation for the Piper Sandler 32 nd Annual Virtual Healthcare Conference.
Read more →HALOHalozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
"We are delighted that Phesgo ® , the first combination of two established monoclonal antibodies with our ENHANZE ® technology, administered in just 5-8 minutes, is one step closer to becoming available for patients with HER-2 positive breast cancer in the EU," said Dr. Helen Tor
Read more →HALOHalozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S....
SAN DIEGO , Nov. 12, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of
Read more →HALOHalozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating...
SAN DIEGO , Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC) daratumumab utilizing ENHANZE ® will be the subject of presentations at the up
Read more →HALOHALOZYME REPORTS THIRD QUARTER 2020 RESULTS AND RAISES FULL YEAR 2020 GUIDANCE - Reports Third Quarter 2020 Revenue of $65.3 million and Earnings Per Share of $0.25 - - Successful Launch of DARZALEX SC with ENHANZE Drive
HALOZYME REPORTS THIRD QUARTER 2020 RESULTS AND RAISES FULL YEAR 2020 GUIDANCE - Reports Third Quarter 2020 Revenue of $65.3 million and Earnings Per Share of $0.25 - - Successful Launch of DARZALEX SC with ENHANZE Drives 44% Year-over-year and 51% Sequential Growth in Royaltie
Read more →HALOHalozyme To Host THIRD Quarter 2020 Financial Results webcast and Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2020 on Monday, November 2 at 4:30 ...
SAN DIEGO , Oct. 22, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the third quarter 2020 on Monday, November 2 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will
Read more →HALOHalozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license...
SAN DIEGO , Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019 . Under the newly announced expansion, argenx ga
Read more →HALOHalozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b...
SAN DIEGO , Sept. 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating atezolizumab (Tecentriq ® ) for subcutaneous administration u
Read more →HALOHalozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a supplemental...
SAN DIEGO , Sept. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking ap
Read more →HALOHalozyme To Present At Upcoming Virtual Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the ...
SAN DIEGO , Sept. 9, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will be participating in the following investor conferences: A live webcast of each event can be accessed through
Read more →HALOHalozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the...
SAN DIEGO , Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will participate in the upcoming 2020 Wells Fargo Virtual Healthcare Conference. Dr. Torley will take part in a fir
Read more →HALOHALOZYME REPORTS SIGNIFICANT RECENT ACHIEVEMENTS AND SECOND QUARTER 2020 RESULTS - Reports First Quarter of Expected Sustainable Profitability and Maintains 2020 Guidance of $230 to $245 Million in Revenues and $0.60 to
HALOZYME REPORTS SIGNIFICANT RECENT ACHIEVEMENTS AND SECOND QUARTER 2020 RESULTS - Reports First Quarter of Expected Sustainable Profitability and Maintains 2020 Guidance of $230 to $245 Million in Revenues and $0.60 to $0.75 Earnings Per Share - - Two U.S. FDA Approvals and On
Read more →HALOHalozyme To Present At Canaccord Genuity 40th Annual Growth Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the...
SAN DIEGO , Aug. 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will participate in the upcoming Canaccord Genuity 40th Annual Growth Conference. Dr. Torley will take part in a fir
Read more →HALOHalozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2020 on Monday, August 10 at 4:30 ...
SAN DIEGO , July 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the second quarter 2020 on Monday, August 10 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will
Read more →HALOHalozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, ...
SAN DIEGO , June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, a fixed-dose combination (FDC) of Perje
Read more →HALOHalozyme To Receive $10 Million Milestone Payment From Janssen Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $10 million milestone payment from Janssen Biotech, Inc....
SAN DIEGO , June 22, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the company will receive a $10 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies. T
Read more →HALOHalozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the ...
SAN DIEGO , June 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Dr. Helen Torley , president and chief executive officer, will be participating in the upcoming BMO 2020 Prescriptions for Success Healthcare Conference, which is being held
Read more →HALOHalozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III...
SAN DIEGO , June 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC) daratumumab utilizing ENHANZE ® in combination
Read more →HALOHalozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted Janssen-Cilag International NV (Janssen)...
SAN DIEGO , June 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the European Commission (EC) has granted Janssen-Cilag International NV (Janssen) marketing authorization for the subcutaneous (SC) formulation of DARZALEX ® (daratumumab), f
Read more →HALOHalozyme To Receive $15 Million Milestone Payment From Janssen Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $15 million milestone payment from Janssen Biotech, Inc....
SAN DIEGO , May, 14, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the company will receive a $15 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies. T
Read more →HALOHALOZYME REPORTS FIRST QUARTER 2020 RESULTS - DARZALEX FASPRO TM Utilizing ENHANZE Technology Receives U.S. FDA Approval with Subcutaneous Administration Time of 3 - 5 Minutes and Lower Rate of Administration-related Rea
HALOZYME REPORTS FIRST QUARTER 2020 RESULTS - DARZALEX FASPROTM Utilizing ENHANZE Technology Receives U.S. FDA Approval with Subcutaneous Administration Time of 3 - 5 Minutes and Lower Rate of Administration-related Reactions When Compared with IV DARZALEX - - Positive CHMP Opi
Read more →HALOHalozyme Reports First Quarter 2020 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2020 and provided an update on its...
SAN DIEGO , May 11, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the first quarter ended March 31, 2020 and provided an update on its recent corporate activities and outlook. "This has been a very exciting start to the yea
Read more →HALOHalozyme To Present At The Bank Of America Securities 2020 Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), will participate in the Bank of America Securities 2020 Healthcare Conference. This conference is being...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), will participate in the Bank of America Securities 2020 Healthcare Conference. This conference is being hosted virtually. Dr. Helen Torley , president and chief executive officer, will provide an
Read more →HALOHalozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO™ Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has received approval from the U.S....
SAN DIEGO , May 1, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for DARZALEX FASPRO ™ (daratumumab hyaluronidase human-
Read more →HALOHalozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen-Cilag International NV (Janssen) received a Committee for Medicinal Products...
SAN DIEGO , April 30, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Janssen-Cilag International NV (Janssen) received a Committee for Medicinal Products for Human Use (CHMP) Positive Opinion from the European Medicines Agency (EMA) recommen
Read more →HALOHalozyme To Host First Quarter 2020 Financial Results Webcast and Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2020 on Monday, May 11 at 4:30 p.m....
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the first quarter 2020 on Monday, May 11 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will le
Read more →HALOHalozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and...
SAN DIEGO , April 26, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) by Janssen Pharmaceutical K.K. (Janssen) seeking approval of a new subcutaneo
Read more →HALOHalozyme Announces Change Of Location Of Annual Stockholders' Meeting Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that due to the emerging public health impact of the coronavirus outbreak (COVID-19), to...
SAN DIEGO , April 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that due to the emerging public health impact of the coronavirus outbreak (COVID-19), to support the health and well-being of our employees and stockholders, and to comply with t
Read more →HALOHalozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4 at...
SAN DIEGO , Feb. 26, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4 at 11:20 a.m. ET / 8:20 a.m. PT in Boston . Dr. Helen Torley , president and chief executive
Read more →HALOHalozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration has accepted a Biologics License Application...
SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech, a member of the Roche Group, for the fixed-dose combination of pertu
Read more →HALOHalozyme Announces CFO Transition Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine D. Sun has been appointed senior vice president and chief financial officer,...
SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Elaine D. Sun has been appointed senior vice president and chief financial officer, effective March 2, 2020 . Ms. Sun will succeed Laurie Stelzer , who has resigned to pursue
Read more →HALOHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS - Halozyme Reiterates 2020 Guidance of $230 to $245 Million in Revenues and $0.60 to $0.75 Earnings Per Share with Profitability Beginning in Second Quarter - -T
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS - Halozyme Reiterates 2020 Guidance of $230 to $245 Million in Revenues and $0.60 to $0.75 Earnings Per Share with Profitability Beginning in Second Quarter - -Two ENHANZE Partnered Drugs Now Under US and EU Regulatory
Read more →HALOHalozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2019 on Monday, February 24 at...
SAN DIEGO , Feb. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the fourth quarter 2019 on Monday, February 24 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, wi
Read more →HALOHalozyme Provides 2020 Business Update And Financial Guidance Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on its outlook for 2020, including financial guidance. We have made tremendous...
SAN DIEGO , Jan. 14, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today provided an update on its outlook for 2020, including financial guidance. "We have made tremendous progress repositioning the company to focus solely on driving the growth and profitabili
Read more →HALOHalozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday,...
SAN DIEGO , Jan. 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 8:30 a.m. PT / 11:30 a.m. ET . Dr. Helen Torley , president and chief executive
Read more →HALOData From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of ...
SAN DIEGO , Dec. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, will be presented today at the 2019 San Antonio Breast Cancer Symposiu
Read more →HALOHalozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the Company ), a biotechnology company focused on novel biological and drug delivery approaches, today...
SAN DIEGO , Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal amount of its convertible sen
Read more →HALOHalozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 SAN DIEGO, CA (
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 SAN DIEGO, CA (November 13, 2019) Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the Company ), a biotechnology company focused on novel biological and drug deli
Read more →HALOHALOZYME REPORTS THIRD QUARTER 2019 RESULTS - Total Revenues Increase 81% to $46.2 million Compared to $25.6 million in Prior-year Period - - First Quarter of Sustainable Profitability Expected in Second Quarter of 2020
HALOZYME REPORTS THIRD QUARTER 2019 RESULTS - Total Revenues Increase 81% to $46.2 million Compared to $25.6 million in Prior-year Period - - First Quarter of Sustainable Profitability Expected in Second Quarter of 2020 - - Board Authorizes Initiation of Capital Return with Sh
Read more →HALOHalozyme Reports Third Quarter 2019 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2019 and provided an update on...
SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its recent corporate activities and outlook. "We have transitioned our strategy to focu
Read more →HALOHalozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024 Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the Company ), a biotechnology company focused on novel biological and drug delivery approaches, today...
SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced that it intends to offer, subject to market conditions and other factors, $400
Read more →HALOHalozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE® drug...
SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE ® drug delivery technology. In order to implement this strategic shift, Halozyme will immediately i
Read more →HALOHalozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a...
SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to re
Read more →HALOHalozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , Oct. 21, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2019 on Tuesday, November 12 at 4:30 p.m.
Read more →HALOHalozyme To Participate In 2019 Cantor Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the...
SAN DIEGO , Sept. 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Cantor Global Healthcare Conference in New York, NY . Dr. Helen Torley , president a
Read more →HALOPositive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the...
SAN DIEGO , Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met
Read more →HALOpresentation 2019 Wells Fargo Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO
2019 Wells Fargo Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 4, 2019 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statement
Read more →HALOHalozyme To Participate In 2019 Wells Fargo Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the...
SAN DIEGO , Aug. 26, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Wells Fargo Healthcare Conference in Boston, MA. Dr. Helen Torley , president and chi
Read more →HALOHALOZYME REPORTS SECOND QUARTER 2019 RESULTS - Total Revenues Increase 11% to $39.1 million Compared to $35.2 million in Prior-year Period - - ENHANZE Partner Janssen Submits Regulatory Applications for Subcutaneous Form
HALOZYME REPORTS SECOND QUARTER 2019 RESULTS - Total Revenues Increase 11% to $39.1 million Compared to $35.2 million in Prior-year Period - - ENHANZE Partner Janssen Submits Regulatory Applications for Subcutaneous Formulation of DARZALEX in the U.S. and EU - - Pivotal Phase
Read more →HALOHalozyme Reports Second Quarter 2019 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , Aug. 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the second quarter ended June 30, 2019 and provided an update on recent corpor
Read more →HALOHalozyme To Participate In 39th Annual Canaccord Genuity Growth Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the...
SAN DIEGO , July 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 39th Annual Canaccord Genuity Growth Conference in Boston, MA. Laurie Stelzer, senior vice
Read more →HALOHalozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , July 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2019 on Tuesday, August 6 at 4:30 p.m. ET
Read more →HALOHalozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that...
SAN DIEGO , July 19, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen-Cilag International NV (Janssen) has submitted an extension application to the Europe
Read more →HALOHalozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that...
SAN DIEGO , July 17, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmac
Read more →HALOHalozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that its...
SAN DIEGO , July 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a Biologics License Applicatio
Read more →HALOHalozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of...
SAN DIEGO , June 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases' Vaccine Research Center (VRC), part of the National Insti
Read more →HALOHalozyme To Participate In Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two...
SAN DIEGO , June 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences. A live webcast of each session can be accessed through the
Read more →HALOHalozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that...
SAN DIEGO , May 22, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has selected a second target under the collaboration and license agreement the companie
Read more →HALOHalozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the...
SAN DIEGO , May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las Vegas, NV. Laurie Stelzer
Read more →HALOHalozyme Reports First Quarter 2019 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , May 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent corpora
Read more →HALOHALOZYME REPORTS FIRST QUARTER 2019 RESULTS - Revenue of $56.9 Million Compared to $30.9 Million in Prior-year Period - - ENHANZE Partner Receives FDA Approval for Subcutaneous Formulation of Herceptin - - Positive Phase
HALOZYME REPORTS FIRST QUARTER 2019 RESULTS - Revenue of $56.9 Million Compared to $30.9 Million in Prior-year Period - - ENHANZE Partner Receives FDA Approval for Subcutaneous Formulation of Herceptin - - Positive Phase 3 Trial Results Announced for Subcutaneous Formulation o
Read more →HALOHalozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , May 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert Alison A. Armour , M.B. Ch.B., B
Read more →HALOHalozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , April 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the first quarter 2019 on Tuesday, May 7 at 4:30 p.m. ET /
Read more →HALOHalozyme Announces FDA Approval Of Herceptin Hylecta™ Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that...
SAN DIEGO , Feb. 28, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Adm
Read more →HALOHALOZYME REPORTS FOURTH QUARTER AND FULL-YEAR 2018 RESULTS - ENHANZE Technology Licensed to argenx for up to Three Targets, Including Named target FcRn, Resulting in Upfront Payment of $30 Million - - 2019 Guidance Raise
HALOZYME REPORTS FOURTH QUARTER AND FULL-YEAR 2018 RESULTS - ENHANZE Technology Licensed to argenx for up to Three Targets, Including Named target FcRn, Resulting in Upfront Payment of $30 Million - - 2019 Guidance Raised for Net Revenue and Year End Cash Balance to Reflect Lat
Read more →HALOHalozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the fourth quarter 2018 on Thursday, February 21 at 4:30 p.m.
Read more →HALOargenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that...
BREDA , the Netherlands and GHENT, Belgium and SAN DIEGO , Feb. 4, 2019 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX ) and Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE®
Read more →HALOHALOZYME PROVIDES 2019 PIPELINE UPDATE AND FINANCIAL GUIDANCE AT 37 TH ANNUAL JP MORGAN HEALTHCARE CONFERENCE - Anticipated ENHANZE Partner Progress in 2019 Includes One FDA Approval, New Regulatory
HALOZYME PROVIDES 2019 PIPELINE UPDATE AND FINANCIAL GUIDANCE AT 37TH ANNUAL JP MORGAN HEALTHCARE CONFERENCE SAN DIEGO, Jan. 9, 2019 - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided a pipe
Read more →HALOHalozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided a pipeline...
SAN DIEGO , Jan. 9, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today provided a pipeline update and announced its 2019 financial guidance at the 37 th annual JP Morgan Healthcare
Read more →HALOHalozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the...
SAN DIEGO , Dec. 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9 a
Read more →HALOHALOZYME ANNOUNCES CHANGE IN PRIMARY ENDPOINT FOR HALO-301 TO OVERALL SURVIVAL FDA Agrees to Company Request to Change Primary Endpoint to Overall Survival Previously Planned Interim Analysis Will N
HALOZYME ANNOUNCES CHANGE IN PRIMARY ENDPOINT FOR HALO-301 TO OVERALL SURVIVAL FDA Agrees to Company Request to Change Primary Endpoint to Overall Survival Previously Planned Interim Analysis Will Not Be Conducted Management to Host Webcast / Conference Call Today at 5 p.m. ET
Read more →HALOHalozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that prior ...
SAN DIEGO , Nov. 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that prior to data analysis, the FDA has agreed to Halozyme's request to change the primary endpoi
Read more →HALOHalozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that...
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Albert Kildani has joined the company in the role of vice president of investor relations and
Read more →HALOHALOZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS - ENHANZE Licensed to Roche for up to Three Additional Targets, Includes $25 Million Upfront Payment, Plus the Potential for Future Milestone and Royalty Payments - -
HALOZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS - ENHANZE Licensed to Roche for up to Three Additional Targets, Includes $25 Million Upfront Payment, Plus the Potential for Future Milestone and Royalty Payments - - 2018 Guidance Raised for Net Revenue and Year End Cash Ba
Read more →HALOHalozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it...
SAN DIEGO , Oct. 30, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has licensed its ENHANZE ® drug-delivery technology to Roche for exclusive development of
Read more →HALOHalozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Bristol-Myers Squibb (NYSE: BMY) has dosed the first subject in a clinical trial...
SAN DIEGO , Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Bristol-Myers Squibb (NYSE: BMY ) has dosed the first subject in a clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigatio
Read more →HALOHalozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of data from two clinical trials for PEGPH20 (pegvorhyaluronidase alfa)...
SAN DIEGO , Oct. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the presentation of data from two clinical trials for PEGPH20 (pegvorhyaluronidase alfa) in patients with advanced pancreas and metastatic breast cancer. The presentations were m
Read more →HALOHalozyme To Host Third Quarter 2018 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , Oct. 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2018 on Tues., Nov. 6 at 4:30 p.m. ET / 1:
Read more →HALOHalozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , Oct. 4, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the publication of nonclinical data for PEGPH20 in Clinical Cancer Research , an American Associati
Read more →HALOHalozyme Therapeutics To Participate In Upcoming Investor Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the...
SAN DIEGO , Sept. 20, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the 2018 Cantor Global Healthcare Conference in New York on Monday, October 1 at 3:30 p.m. E
Read more →HALOHalozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Roche has received approval from Health Canada for a subcutaneous (SC) formulation of ...
SAN DIEGO , Sept. 17, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Roche has received approval from Health Canada for a subcutaneous (SC) formulation of trastuzumab (Herceptin SC) for the treatment of patients with HER2-positive breast can
Read more →HALOHalozyme Appoints Bernadette Connaughton To Board Of Directors Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , Sept. 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Bernadette Connaughton to its board of directors. Ms. Connaughton brings more
Read more →HALOForward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act o
Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Exhibit 99.1 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the
Read more →HALOHalozyme Names Benjamin Hickey As Chief Commercial Officer Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , Sept. 5, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of pharmaceutical veteran Benjamin Hickey , as chief commercial officer of Halozym
Read more →HALOHalozyme Therapeutics To Participate In Upcoming Investor Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two...
SAN DIEGO , Aug. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences. Dr. Helen Torley , president and chief executive officer o
Read more →HALOHalozyme Reports Second Quarter 2018 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , Aug. 7, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the second quarter ended June 30 . "At the beginning of
Read more →HALORobert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com HALOZYME REPORTS SECOND QUARTER 2018 RESULTS -- Revenue of $35.2 Million
Westwicke Partners, LLC robert.uhl@westwicke.com HALOZYME REPORTS SECOND QUARTER 2018 RESULTS -- Revenue of $35.2 Million Includes a 36 Percent Increase in Royalty Revenue on a Reported Basis -- -- FDA Accepts Roche/Genentech's Filing for Subcutaneous Formulation of Herceptin
Read more →HALOHalozyme Therapeutics To Participate In Upcoming Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the...
SAN DIEGO , July 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Canaccord Genuity 38 th Annual Growth Conference in Boston on Thursday, August 9 at 12:0
Read more →HALOPhase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that...
SAN DIEGO , July 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has dosed the first patient in a Phase 3 study of a f
Read more →HALOFDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License...
SAN DIEGO , July 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application from Genentech, a member of the Roche Group, for a subcutaneous (SC) formulation of
Read more →HALOHalozyme To Host Second Quarter 2018 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , July 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2018 on Tues., Aug. 7 at 4:30 p.m. ET / 1:
Read more →HALOHalozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced Dr. Helen...
SAN DIEGO , June 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced Dr. Helen Torley , president and chief executive officer, was awarded the honor of Entrepreneur Of
Read more →HALOHalozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present data...
SAN DIEGO , June 1, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will present data evaluating certain biomarkers as potential predictors of survival in patients with previously unt
Read more →HALOHalozyme Therapeutics To Participate In Upcoming Healthcare Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two...
SAN DIEGO , May 29, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two upcoming investor conferences. Dr. Helen Torley , president and chief executive officer wil
Read more →HALOHalozyme Reports First Quarter 2018 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , May 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the first quarter ended March 31 . "Reflecting the enth
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS FIRST QUARTER 2018 RESULTS -- Revenue of $30.9 Million Includes a 50 Percent Increase in Royalty Revenue on a
HALOZYME REPORTS FIRST QUARTER 2018 RESULTS -- Revenue of $30.9 Million Includes a 50 Percent Increase in Royalty Revenue on a Reported Basis -- -- Eight ENHANZE -Partnered Products Expected in Clinical Studies in 2018, Two More than Forecasted in January -- -- Target Number o
Read more →HALOHalozyme To Host First Quarter 2018 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , April 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the first quarter 2018 on Thurs., May 10 at 4:30 p.m. ET /
Read more →HALOHalozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , March 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the nomination of Jean-Pierre Bizzari , M.D. and James M. Daly as Class II directors for reelecti
Read more →HALOto such Form 8-K. Board Recommendation and Vote Required As our Board of Directors continues to believe that the number of shares currently available for issuance under the 2011 Plan is not sufficient in view of our comp
HALOZYME THERAPEUTICS, INC. SUPPLEMENT TO PROXY STATEMENT DATED MARCH 22, 2018 Annual Meeting of Stockholders To Be Held on May 2, 2018 To the Stockholders of HALOZYME THERAPEUTICS, INC.: Purpose of Supplement Halozyme Therapeutics, Inc. (the "Company") is furnishing this
Read more →HALOHalozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present nonclinical...
SAN DIEGO , March 14, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will present nonclinical data from six studies at the 109 th annual meeting of the American Association of Cancer
Read more →HALOHalozyme Therapeutics To Present At Upcoming Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the...
SAN DIEGO , Feb. 27, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the Cowen & Company 38 th Annual Healthcare Conference in Boston on Tuesday, March 13 at 9:20
Read more →HALOHalozyme Reports Fourth Quarter And Full-Year 2017 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , Feb. 20, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the fourth quarter and full-year ended December 31, 201
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS FOURTH QUARTER AND FULL-YEAR 2017 RESULTS -- Continued Momentum from ENHANZE Technology with Q4 Royalty Revenu
HALOZYME REPORTS FOURTH QUARTER AND FULL-YEAR 2017 RESULTS -- Continued Momentum from ENHANZE Technology with Q4 Royalty Revenue Increasing 24 Percent from Prior-Year Period to $17.7 million -- -- HALO-301 Study of Investigational New Drug PEGPH20 Remains on Track to Achieve Ta
Read more →HALOHalozyme To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , Jan. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the fourth quarter 2017 on Tues., Feb. 20 at 4:30 p.m. ET /
Read more →HALOHalozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, forecasts 25 to 30 percent ...
SAN DIEGO , Jan. 9, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, forecasts 25 to 30 percent royalty revenue growth in 2018 and potential for royalty revenue to reach nearly $1 bill
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME PORJECTS 25 TO 30 PRECENT ENHANZE ROYALTY GROWTH IN 2018 CONTINUES TO EXPECT TARGET NUMBER OF PFS EVENTS IN HALO-301 R
HALOZYME PORJECTS 25 TO 30 PRECENT ENHANZE ROYALTY GROWTH IN 2018 CONTINUES TO EXPECT TARGET NUMBER OF PFS EVENTS IN HALO-301 REGISTRATION TRIAL TO BE REACHED IN LATE Q4 SAN DIEGO, Jan. 9, 2018 - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing nov
Read more →HALOHalozyme Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the...
SAN DIEGO , Dec. 27, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9 at 3
Read more →HALOHalozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will present nonclinical data at the 32nd Annual Meeting of the Society for...
SAN DIEGO , Nov. 10, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it will present nonclinical data at the 32 nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) which demonstrate the potential for PEGPH20, Halozyme's pegyla
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS THIRD QUARTER 2017 RESULTS -- Strong ENHANZE Momentum Following Landmark Collaboration Agreement with Bristol-
HALOZYME REPORTS THIRD QUARTER 2017 RESULTS -- Strong ENHANZE Momentum Following Landmark Collaboration Agreement with Bristol-Myers Squibb -- -- Royalty Revenue Increased 31 Percent from Prior-Year Period to $17.1 million on Growing Sales of Herceptin SC, MabThera SC in Q2 --
Read more →HALOHalozyme Reports Third Quarter 2017 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , Nov. 7, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the third quarter ended September 30 . "During the thir
Read more →HALOPhase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that...
SAN DIEGO , Oct. 31, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen Biotech, Inc. has initiated the first of three planned Phase 3 clinical trials evalua
Read more →HALOFirst Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the initiation of a multi-arm clinical trial evaluating PEGPH20, Halozyme's...
SAN DIEGO , Oct. 24, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the initiation of a multi-arm clinical trial evaluating PEGPH20, Halozyme's investigational new drug, in combination with atezolizumab (TECENTRIQ ® ), an anti-PDL1 cancer immunot
Read more →HALOHalozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced initiation of a clinical trial evaluating its investigational new drug PEGPH20 with...
SAN DIEGO , Oct. 16, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced initiation of a clinical trial evaluating its investigational new drug PEGPH20 with atezolizumab (TECENTRIQ ® ), an anti-PDL1 cancer immunotherapy from Genentech, a member of the
Read more →HALOHalozyme to Host Third Quarter 2017 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , Oct. 10, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2017 on Tues., Nov. 7 at 4:30 p.m. ET / 1:
Read more →HALOHalozyme Increases 2017 Financial Guidance Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today raised financial...
SAN DIEGO , Sept. 14, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today raised financial guidance for 2017 following the announcement of two new licensing agreements for its ENHAN
Read more →HALOHalozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today it licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an ...
SAN DIEGO , Sept. 14, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today it licensed its ENHANZE ® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic target. Under terms of the agreement, Halozyme will receive
Read more →HALOHalozyme Therapeutics To Present At Upcoming Healthcare Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate at two...
SAN DIEGO , Aug. 25, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies will participate at two upcoming investor conferences. Dr. Helen Torley , president and chief executive officer wi
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS SECOND QUARTER 2017 RESULTS -- Genentech's U.S. RITUXAN HYCELA Launch Underway; Lilly Doses First Patient in C
HALOZYME REPORTS SECOND QUARTER 2017 RESULTS -- Genentech's U.S. RITUXAN HYCELA Launch Underway; Lilly Doses First Patient in Clinical Study of New Investigational Therapy Combined with Halozyme ENHANZE Technology - -- Total Revenue of $33.8 million with Royalty Revenue Increas
Read more →HALOHalozyme Reports Second Quarter 2017 Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , Aug. 8, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the second quarter ended June 30. "A clear highlight of
Read more →HALOInitiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the initiation of a multi-arm clinical trial evaluating PEGPH20, Halozyme's...
SAN DIEGO , July 13, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the initiation of a multi-arm clinical trial evaluating PEGPH20, Halozyme's investigational new drug, in combination with atezolizumab (TECENTRIQ ® ), an anti-PDL1 cancer immunot
Read more →HALOHalozyme To Host Second Quarter 2017 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , July 10, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2017 on Tues., Aug. 8 at 4:30 p.m. ET / 1
Read more →HALOHalozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium Results from Halozyme Therapeutics (NASDAQ: HALO) Phase 2 randomized, multi-center clinical trial in pancreas cancer patients were shared today in...
BARCELONA, Spain , June 28, 2017 /PRNewswire/ -- Results from Halozyme Therapeutics (NASDAQ: HALO ) Phase 2 randomized, multi-center clinical trial in pancreas cancer patients were shared today in two oral presentations at the European Society for Medical Oncology's 19 th World C
Read more →HALOFDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the U....
SAN DIEGO , June 22, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved Genentech's RITUXAN HYCELATM, a comb
Read more →HALOHalozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO Encouraging results from a Phase 2 randomized, multi-center clinical trial in pancreas cancer patients conducted by Halozyme Therapeutics (NASDAQ:...
CHICAGO , June 4, 2017 /PRNewswire/ -- Encouraging results from a Phase 2 randomized, multi-center clinical trial in pancreas cancer patients conducted by Halozyme Therapeutics (NASDAQ: HALO ) were presented today at the American Society of Clinical Oncology (ASCO) annual confere
Read more →HALOHalozyme Therapeutics To Present At Upcoming Healthcare Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting a...
SAN DIEGO , May 25, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting a corporate overview at three upcoming investor conferences. Laurie Stelzer , senior vice presid
Read more →HALOHalozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the completion of its previously announced underwritten public offering of 11,500,000...
SAN DIEGO , May 24, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today the completion of its previously announced underwritten public offering of 11,500,000 shares of its common stock. The offering included 1,500,000 shares sold pursuant to the full
Read more →HALOHalozyme Therapeutics Prices Public Offering Of Common Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the pricing of its previously announced underwritten public offering of 10,000,000 shares...
SAN DIEGO , May 18, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $12.50 per share. All of the shares in
Read more →HALOHalozyme Therapeutics Announces Public Offering Of Common Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has commenced an underwritten public offering of $100,000,000 of shares of its...
SAN DIEGO , May 18, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares in the offering are to be sold by Halozyme. Halozyme intends
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com
HALOZYME THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, May 18, 2017 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares in the offer
Read more →HALOHalozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO Results from a Phase 2 randomized, multi-center clinical trial in pancreas cancer patients conducted by Halozyme Therapeutics (NASDAQ: HALO) of its...
SAN DIEGO , May 17, 2017 /PRNewswire/ -- Results from a Phase 2 randomized, multi-center clinical trial in pancreas cancer patients conducted by Halozyme Therapeutics (NASDAQ: HALO ) of its targeted investigational therapy, PEGPH20, will be presented in an oral presentation on Ju
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS FIRST QUARTER 2017
HALOZYME REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS SAN DIEGO, May 9, 2017 - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the first quarter
Read more →HALOHalozyme Reports First Quarter 2017 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , May 9, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the first quarter ended March 31, 2017. "The first quart
Read more →HALOHalozyme To Host First Quarter 2017 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , April 10, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the first quarter 2017 on Tues., May 9 at 4:30 p.m. ET / 1:
Read more →HALOHalozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, demonstrated in...
SAN DIEGO , April 3, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, demonstrated in preclinical models that its investigational drug PEGPH20 increases the number of cancer-fighting w
Read more →HALOHalozyme Provides Update On SWOG Collaborative Group Clinical Study Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it has been informed by SWOG, an independent network of researchers that design and...
SAN DIEGO , March 30, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced it has been informed by SWOG, an independent network of researchers that design and conduct cancer clinical trials, that the SWOG Phase 1b/2 trial evaluating PEGPH20 plus modifi
Read more →HALOFDA Advisory Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated With Halozyme Enhanze Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that an...
SAN DIEGO , March 29, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that an Oncologic Drug Advisory Committee of the U.S. Food and Drug Administration voted 11 to 0
Read more →HALOHalozyme Reports Fourth Quarter And Full Year 2016 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , Feb. 28, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 201
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS - Strong progress in global HALO 301 clinical trial follow
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS - Strong progress in global HALO 301 clinical trial following positive randomized Phase 2 HALO- 202 results - - Supportive partner data presented at ASH in two key ENHANZE platform programs - - 2016 Royalty R
Read more →HALOHalozyme Therapeutics To Present At Upcoming Healthcare Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the...
SAN DIEGO , Feb. 23, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Cowen & Company 37 th Annual Healthcare Conference in Boston on Tuesday, March 7 at 11:2
Read more →HALOHalozyme To Host Fourth Quarter 2016 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , Feb. 1, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the fourth quarter 2016 on Tues., Feb. 28, 2017 at 4:30 p.m.
Read more →HALOHalozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided program...
SAN DIEGO , Jan. 9, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today provided program updates and its annual financial guidance at the 35 th annual JP Morgan Healthcare Conferenc
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME PROVIDES PROGRAM UPDATES, 2017 FINANCIAL GUIDANCE AT 35
HALOZYME PROVIDES PROGRAM UPDATES, 2017 FINANCIAL GUIDANCE AT 35TH ANNUAL JP MORGAN HEALTHCARE CONFERENCE SAN DIEGO, Jan. 9, 2017 - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided program u
Read more →HALOHalozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO...
SAN DIEGO , Jan. 5, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study, a Phase 2 randomized, multi-center clinical trial of lead investigational drug
Read more →HALOHalozyme Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the...
SAN DIEGO , Dec. 22, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the 35 th Annual J.P. Morgan Healthcare Conference in San Francisco on Mon., Jan. 9 at 3:00
Read more →HALOHalozyme Provides Update On AbbVie Collaboration Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform...
SAN DIEGO , Nov. 21, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of
Read more →HALOHalozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, and Genentech, a member of the ...
SAN DIEGO , Nov. 10, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), an oncology biotech developing novel oncology and drug-delivery therapies, and Genentech, a member of the Roche Group, today announced an agreement to collaborate on clinical studies evaluating
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS - Strong progress initiating global sites for HALO-301 study and toward d
HALOZYME REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS - Strong progress initiating global sites for HALO-301 study and toward dose expansion of PEGPH20/KEYTRUDA clinical study - - ENHANZE platform royalty potential grows through FDA accepting Roche/Genentech's filing for subcut
Read more →HALOHalozyme Reports Third Quarter 2016 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results and recent highlights for the third quarter ended September 30. The...
SAN DIEGO , Nov. 7, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results and recent highlights for the third quarter ended September 30 . "The third quarter was highlighted by Genentech's BLA filing for rituximab in a subcutaneous for
Read more →HALOFDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has accepted Genentech's Biologics...
SAN DIEGO , Nov. 3, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) has accepted Genentech's Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer indica
Read more →HALOHalozyme To Host Third Quarter 2016 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly ...
SAN DIEGO , Oct. 13, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2016 on Mon., Nov. 7, 2016 at 4:30 p.m. ET
Read more →HALOPEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, today announced that its...
President and CEO Dr. Helen Torley said: "Halozyme is proud to be participating in this important initiative that has the potential to change how pancreas cancer is treated and improve outcome for patients. I want to recognize The Pancreatic Cancer Action Network for their vision
Read more →HALOHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the...
SAN DIEGO , Sept. 8, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Bank of America Merrill Lynch 2016 Global Health Care Conference in London , on Thurs.,
Read more →HALOHalozyme Names Mark J. Gergen As Chief Operating Officer Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran...
SAN DIEGO , Sept. 1, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Hele
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS - Revenue guidance raised to a range of $140 million to $150 million fro
HALOZYME REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS - Revenue guidance raised to a range of $140 million to $150 million from prior range of $130 million to $145 million - - Strong progress in HALO-301 Phase 3 trial with site initiations in Europe, Asia Pacific and the Unite
Read more →HALOHalozyme Reports Second Quarter 2016 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results and recent highlights for the second quarter ended June 30. I am very...
SAN DIEGO , Aug. 9, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results and recent highlights for the second quarter ended June 30 . "I am very pleased with the strong momentum in our ENHANZE™ platform leading to today's increase in
Read more →HALOEisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Eisai Inc. has dosed the first patient in a collaborative phase 1b/2 clinical trial...
SAN DIEGO , July 26, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that Eisai Inc. has dosed the first patient in a collaborative phase 1b/2 clinical trial to assess whether Eisai's eribulin mesylate (HALAVEN ® ) in combination with Halozyme's i
Read more →HALOHalozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial...
SAN DIEGO , July 25, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its investigational new drug, PEGPH20, in combination with KEYTRUDA (pembrolizu
Read more →HALOHalozyme To Host Second Quarter 2016 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2016 on Tuesday, August 9, 2016...
SAN DIEGO , July 11, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the second quarter 2016 on Tuesday, August 9, 2016 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME ANNOUNCES AGREEMENT TO REFINANCE DEBT, INCREASES 2016 GUIDANCE FOR YEAR-END CASH BALANCE - Interest-only repayment pro
HALOZYME ANNOUNCES AGREEMENT TO REFINANCE DEBT, INCREASES 2016 GUIDANCE FOR YEAR-END CASH BALANCE - Interest-only repayment provision results in $44 million increase to expected cash balance through 2017- - New debt facility provides option to borrow additional $15 million in
Read more →HALOHalozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it...
SAN DIEGO , June 8, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has entered into an agreement with Oxford Finance LLC and Silicon Valley Bank to refinance
Read more →HALOHalozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced results...
SAN DIEGO , June 4, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced results from a final analysis of 135 metastatic pancreatic cancer patients who were treated in Stag
Read more →HALOHalozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2016 Global Health Care Conference in New York, on Tuesday, May 24 at 2:30 p....
SAN DIEGO , May 17, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the UBS 2016 Global Health Care Conference in New York , on Tuesday, May 24 at 2:30 p.m. ET / 11:30 a.m. PT . Laurie Stelzer , chief financial officer, will provide a corpor
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS - Revenue of $42.5 million compared to $18.7 million in prior-year period
HALOZYME REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS - Revenue of $42.5 million compared to $18.7 million in prior-year period, Royalty Revenue of $11.4 million increased 68 percent from prior year - - Revenue guidance raised to a range of $130 million to $145 million and year
Read more →HALOHalozyme Reports First Quarter 2016 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, which included an increase in...
SAN DIEGO , May 9, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the first quarter ended March 31 , which included an increase in revenue of 128 percent from the prior-year period and a net loss of $19.8 million , or $0.16 p
Read more →HALOHalozyme to Host First Quarter 2016 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter on Monday, May 9 at 4:30 p.m....
SAN DIEGO , April 20, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the first quarter on Monday, May 9 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will lead the
Read more →HALOHalozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data ...
SAN DIEGO , April 18, 2016 /PRNewswire/ -- Halozyme Therapeutics (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data for the discovery and early development of two potential drug candidates, an immune ch
Read more →HALOHalozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research Annual Conference Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present preclinical data...
SAN DIEGO , March 17, 2016 /PRNewswire/ -- Halozyme Therapeutics (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will present preclinical data from five studies at the American Association of Cancer Research (AACR) annual conference
Read more →HALOHalozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first...
SAN DIEGO , March 16, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in
Read more →HALOHalozyme Appoints Jim Daly To Board Of Directors Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , March 7, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Jim Daly to its board of directors. Mr. Daly is a biopharmaceutical executive w
Read more →HALOHalozyme Therapeutics To Present At Upcoming Healthcare Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen & Company 36th Annual Healthcare Conference in Boston on Wednesday, March...
SAN DIEGO , March 2, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Cowen & Company 36 th Annual Healthcare Conference in Boston on Wednesday, March 9 at 8:40 a.m. ET / 5:40 a.m. PT . On Tuesday, March 15 , Halozyme will also present at
Read more →HALOHalozyme Reports Fourth Quarter And Full Year 2015 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2015, which...
SAN DIEGO , Feb. 29, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the fourth quarter and full year ended December 31, 2015 , which included a fourth quarter increase in royalty revenue of 136 percent from the prior year per
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS - Investigational device exemption submitted to FDA, on tr
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2015 - Investigational device exemption submitted to FDA, on track for first patient dosing in March in Phase 3 Study of metastatic pancreatic cancer patients - - Growing momentum in ENHANZE franchise with recent signing of Lilly co
Read more →HALOHalozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2015 on Monday,...
SAN DIEGO , Feb. 1, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2015 on Monday, February 29 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executiv
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME ANNOUNCES CLOSING OF $150 MILLION ROYALTY-BACKED
Contacts: Jim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME ANNOUNCES CLOSING OF $150 MILLION ROYALTY-BACKED DEBT FINANCING SAN DIEGO, January 26, 2016 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has closed
Read more →HALOHalozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has closed the previously announced $150 million royalty-backed debt transaction...
SAN DIEGO , Jan. 26, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The
Read more →HALOHalozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE™ Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and...
SAN DIEGO , Jan. 21, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE™ technology. "We are ple
Read more →HALOth Annual J.P. Morgan Healthcare Conference Platforms for Growth: Building a Premier Oncology Biotech Dr. Helen Torley President & CEO
34th Annual J.P. Morgan Healthcare Conference Platforms for Growth: Building a Premier Oncology Biotech Dr. Helen Torley President & CEO January 12, 2016 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME PROVIDES KEY PROGRAM UPDATES, 2016 FINANCIAL GUIDANCE AT 34 TH ANNUAL JP MORGAN HEALTHCARE CONFE
Contacts: Jim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME PROVIDES KEY PROGRAM UPDATES, 2016 FINANCIAL GUIDANCE AT 34TH ANNUAL JP MORGAN HEALTHCARE CONFERENCE Achieved Targeted Patient Enrollment in Phase 2 Metastatic Pancreati
Read more →HALOHalozyme Provides Key Program Updates, 2016 Financial Guidance At 34th Annual JP Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided key program ...
SAN DIEGO , Jan. 11, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today provided key program updates and its Annual financial guidance at the 34 th annual JP Morgan Healthcare Conf
Read more →HALOHalozyme Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday,...
SAN DIEGO , Jan. 5, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 12, 2016 at 4:00 p.m. PT / 7:00 p.m. ET . Dr. Helen Torley , president and chief execu
Read more →HALOJim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME ENTERS INTO AGREEMENT FOR $150 MILLION NON-DILUTIVE ROYALTY-BACKED
Contacts: Jim Mazzola 858-704-8122 ir@halozyme.com Chris Burton 858-704-8352 ir@halozyme.com HALOZYME ENTERS INTO AGREEMENT FOR $150 MILLION NON-DILUTIVE ROYALTY-BACKED DEBT FINANCING SAN DIEGO, January 4, 2016 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced
Read more →HALOHalozyme Enters Into Agreement For $150 Million Non-Dilutive Royalty-Backed Debt Financing Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has entered into a $150 million credit agreement, secured by future royalties of...
SAN DIEGO , Jan. 4, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it has entered into a $150 million credit agreement, secured by future royalties of ENHANZE ™ products, received only from Halozyme's collaborations with Roche and Baxalta.
Read more →HALOHalozyme Enters Into Global Collaboration And Licensing Agreement With Lilly Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) to...
SAN DIEGO , Dec. 21, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY ) to develop and commercialize products combining proprietary Lilly compounds with Halozyme's E
Read more →HALOHalozyme Therapeutics To Present At Upcoming Healthcare Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 2 at 9:30 ...
SAN DIEGO , Nov. 24, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 2 at 9:30 a.m. ET / 6:30 a.m. PT . Dr. Helen Torley , president and CEO, will provide a corporate
Read more →HALOHalozyme To Expand With A Satellite Office In San Francisco Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it will be ...
SAN DIEGO , Nov. 17, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it will be expanding its facilities by opening a satellite office on Gateway Boulevard in South Sa
Read more →HALOJim Mazzola Halozyme Therapeutics 858-704-8122 ir@halozyme.com HALOZYME REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS - Revenue of $20.8 million increased 42 percent from prior-year period - - Royalty Revenue of
Halozyme Therapeutics HALOZYME REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS - Revenue of $20.8 million increased 42 percent from prior-year period - - Royalty Revenue of $8.3 million increased nearly 200 percent from prior-year period - - Company on track to close enrollment
Read more →HALOHalozyme Reports Third Quarter 2015 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , Nov. 9, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the third quarter ended September 30, 2015 . Revenue for the quarter of $20.8
Read more →HALOFirst Patient Dosed in Clinical Trial of Halozyme Investigational Drug PEGPH20 in Combination With Merck Immuno-oncology Drug KEYTRUDA Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the first patient has received its investigational new drug, PEGPH20 in combination with...
SAN DIEGO , Nov. 5, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the first patient has received its investigational new drug, PEGPH20 in combination with Merck's KEYTRUDA (pembrolizumab) in a clinical trial to determine the maximum tolerated do
Read more →HALOHalozyme Announces First Clinical Dosing Of Janssen's Daratumumab Using ENHANZE™ Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating...
SAN DIEGO , Nov. 4, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE™ technology in
Read more →HALOHalozyme Therapeutics To Present At The Credit Suisse Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday,...
SAN DIEGO , Nov. 3, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 11, 2015 at 4:00 p.m. ET / 2:00 p.m. MT / 1:00 p.m. PT . Dr. Helen Torley , president a
Read more →HALOHalozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze™ Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the...
SAN DIEGO , Oct. 29, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a
Read more →HALOHalozyme To Host Third Quarter 2015 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2015 on Monday, November 9 at 4:30 ...
SAN DIEGO , Oct. 19, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the third quarter 2015 on Monday, November 9 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will
Read more →HALOHalozyme Appoints Michael J. Labarre As Chief Scientific Officer Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today named Michael J....
SAN DIEGO , Aug. 24, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today named Michael J. LaBarre , Ph.D. as chief scientific officer, succeeding Dr. Michael Shepard , who was appoi
Read more →HALOSchond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Jim Mazzola Halozyme Therapeutics 858-704-8122 ir@halozyme.com HALOZYME REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS - Record revenue of $43.4
Halozyme Therapeutics Halozyme Therapeutics HALOZYME REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS - Record revenue of $43.4 million and net income of $3 million driven by $23 million initiation of AbbVie collaboration - - Revenue, expense and cash use guidance updated for 20
Read more →HALOHalozyme Reports Second Quarter 2015 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , Aug. 10, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the second quarter ended June 30, 2015 . Financial highlights include revenue
Read more →HALOUCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Pancreas Center at the University of California, San Francisco (UCSF) has initiated a...
SAN DIEGO , Aug. 6, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced the Pancreas Center at the University of California, San Francisco (UCSF) has initiated a clinical research study of Halozyme's investigational new drug, PEGPH20 in pancreatic can
Read more →HALOSchond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Jim Mazzola Halozyme Therapeutics 858-704-8122 ir@halozyme.com HALOZYME APPOINTS JEFFREY W. HENDERSON TO BOARD - Henderson brings deep financia
Contacts: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Jim Mazzola Halozyme Therapeutics 858-704-8122 ir@halozyme.com HALOZYME APPOINTS JEFFREY W. HENDERSON TO BOARD - Henderson brings deep financial and pharmaceutical industry expertise, most rec
Read more →HALOHalozyme Appoints Jeffrey W. Henderson To Board Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , Aug. 5, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Jeffrey W. Henderson to its board of directors. Henderson brings nearly 30 years
Read more →HALOHalozyme to Host Second Quarter 2015 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2015 on Monday, August 10, 2015...
SAN DIEGO , Aug. 3, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the second quarter 2015 on Monday, August 10, 2015 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer,
Read more →HALOHalozyme Therapeutics To Present At The JMP Securities 2015 Life Sciences Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will present at the JMP Securities 2015 Life Sciences Conference in New York, on Wednesday, June 24 at...
SAN DIEGO , June 19, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will present at the JMP Securities 2015 Life Sciences Conference in New York , on Wednesday, June 24 at 1:00 p.m. ET / 10:00 a.m. PT . Schond Greenway, executive director, strategy and investor
Read more →HALOSchond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Jim Mazzola Halozyme Therapeutics 858-704-8122 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME ANNOUNCES PLANS FOR CFO TRANSITION
Contacts: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Jim Mazzola Halozyme Therapeutics 858-704-8122 ir@halozyme.com HALOZYME ANNOUNCES PLANS FOR CFO TRANSITION, NAMES LAURIE STELZER CFO June 5, 2015 Halozyme Therapeut
Read more →HALOHalozyme Announces Plans For CFO Transition, Names Laurie Stelzer CFO Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech company, today announced its chief financial officer David Ramsay will retire this...
SAN DIEGO , June 5, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), an oncology biotech company, today announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume CFO
Read more →HALOHalozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with AbbVie (NYSE: ABBV) to develop and...
SAN DIEGO , June 3, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced a global collaboration and license agreement with AbbVie (NYSE: ABBV ) to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE ™ platf
Read more →HALOHalozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim...
SAN DIEGO , May 31, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 fo
Read more →HALOHalozyme Therapeutics To Present At The UBS 2015 Global Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will present at the UBS 2015 Global Health Care Conference in New York, on Monday, May 18th, 2015 at 2:00...
SAN DIEGO , May 12, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will present at the UBS 2015 Global Health Care Conference in New York , on Monday, May 18 th , 2015 at 2:00 p.m. ET / 11:00 a.m. PT . Dr. Helen Torley , president and chief executive officer, wi
Read more →HALOSchond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Jim Mazzola Halozyme Therapeutics 858-704-8122 ir@halozyme.com HALOZYME REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Revenues increase 56 per
Halozyme Therapeutics Halozyme Therapeutics HALOZYME REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Revenues increase 56 percent to $18.7 million, loss narrows to $15.1 million - - Royalty revenue increases 70 percent from the fourth quarter- - Interim results of Halozyme's
Read more →HALOHalozyme Reports First Quarter 2015 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial...
SAN DIEGO , May 11, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the first quarter ended March 31, 2015 . Financial highlights include revenues
Read more →HALOHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas, on...
SAN DIEGO , May 7, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas , on Thursday, May 14, 2015 at 10:40 a.m. PT / 1:40 p.m. ET . David Ramsay , chief financial office
Read more →HALOHalozyme To Host First Quarter 2015 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2015 on Monday, May 11, 2015 at...
SAN DIEGO , May 4, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the first quarter 2015 on Monday, May 11, 2015 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will
Read more →HALOHalozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today shared highlights of ...
SAN DIEGO , April 20, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today shared highlights of new data it presented at the American Association for Cancer Research (AACR) annual me
Read more →HALOHalozyme Therapeutics Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , April 13, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Harry J. Leonhardt, Esq. , as senior vice president, general counsel and chief
Read more →HALOHalozyme Provides Update Following Type B FDA Meeting Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it plans...
SAN DIEGO , April 8, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it plans to proceed with a Phase 3 clinical study (Study 301) of its investigational new drug PEGP
Read more →HALOHalozyme Therapeutics Appoints James Mazzola To Lead Corporate Communications, Investor Relations Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...
SAN DIEGO , March 23, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of James S. Mazzola as vice president, Corporate Communications and Investor Rela
Read more →HALOHalozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous formulation...
SAN DIEGO , March 10, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) reported today that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous formulation of the anti-CD38 antibody daratumumab using the ENHANZE™ technology. In December 2014 ,
Read more →HALOHalozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2015 Global Healthcare Conference in Miami, FL on March 10, 2015 at...
SAN DIEGO , March 3, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Barclays 2015 Global Healthcare Conference in Miami, FL on March 10, 2015 at 1:05 p.m. ET / 10:05 a.m. PT . David A. Ramsay , Chief Financial Officer, will provide a co
Read more →HALOInvestor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Media Contact: Susan Neath Francis 212-301-7182 sfrancis@w2ogroup.com HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESU
Halozyme Therapeutics sfrancis@w2ogroup.com HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2014 - Study 202 interim results presented, evaluating investigational new drug PEGPH20 with gemcitabine and ABRAXANE (nab-paclitaxel) in Stage IV pancreatic cancer patients - - Continu
Read more →HALOHalozyme Reports Fourth Quarter And Full Year 2014 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2014. Financial...
SAN DIEGO , March 2, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the fourth quarter and full year ended December 31, 2014 . Financial highlights for the fourth quarter include revenues of $30.4 million and a net loss of $5
Read more →HALOHalozyme to Host Fourth Quarter and 2014 Year-End Financial Results Conference Call alozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2014 on Monday,...
SAN DIEGO , Feb. 23, 2015 /PRNewswire/ --Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2014 on Monday, March 2, 2015 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , President and Chief Execut
Read more →HALOHalozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the manuscript Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody...
SAN DIEGO , Feb. 17, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the manuscript "Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy" has been published in Molecular Cancer Therapeutics ( February 2015 14:523-532).
Read more →HALOHalozyme Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari brings ...
SAN DIEGO , Jan. 21, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the appointment of Jean-Pierre Bizzari , M.D. to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. "I am delighted to welcome Jean-Pi
Read more →HALOInvestor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Media Contact: Susan Neath Francis 212-301-7182 sfrancis@w2ogroup.com HALOZYME THERAPEUTICS PROVIDES AN UPDATE ON ANTICIPATED MILESTONE
Halozyme Therapeutics sfrancis@w2ogroup.com HALOZYME THERAPEUTICS PROVIDES AN UPDATE ON ANTICIPATED MILESTONES FOR 2015 AT THE 33RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - Evaluating and advancing investigational PEGPH20 in two cancer settings associated with low survival -
Read more →HALOHalozyme Therapeutics Provides An Update On Anticipated Milestones For 2015 At The 33rd Annual J. P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on anticipated 2015 corporate milestones. Our progress in 2014 has set the stage ...
SAN DIEGO , Jan. 12, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today provided an update on anticipated 2015 corporate milestones. "Our progress in 2014 has set the stage for a meaningful 2015, a year in which we plan to further elucidate the potential of o
Read more →HALOInvestor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Media Contact: Susan Neath Francis 212-301-7182 sfrancisw2ogroup.com Halozyme provides AGENDA highlights for analyst and investor meeti
Halozyme Therapeutics sfrancisw2ogroup.com Halozyme provides AGENDA highlights for analyst and investor meeting - Discuss interim results for Study 202 evaluating PEGPH20 with gemcitabine and ABRAXANE in pancreatic cancer patients - - Review current clinical development plan
Read more →HALOHalozyme Provides Agenda Highlights For Analyst And Investor Meeting Halozyme Therapeutics, Inc. (NASDAQ: HALO) today will review the PEGPH20 development program and provide 2015 financial guidance during a meeting for ...
SAN DIEGO , Jan. 7, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today will review the PEGPH20 development program and provide 2015 financial guidance during a meeting for analysts and investors in New York at 10:00 a.m. ET / 7:00 a.m. PT . "We are committed
Read more →HALOHalozyme Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday,...
SAN DIEGO , Jan. 6, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2015 at 4:00 p.m. PT / 7:00 p.m. ET . Dr. Helen Torley , President and Chief Execu
Read more →HALOHalozyme Therapeutics Appoints Athena Countouriotis, M.D. as Chief Medical Officer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Athena Countouriotis, M.D., as Chief Medical Officer where she will be...
SAN DIEGO , Jan. 5, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the appointment of Athena Countouriotis, M.D., as Chief Medical Officer where she will be responsible for directing Halozyme's research, clinical development and regulatory activi
Read more →HALOHalozyme Therapeutics To Host Analyst And Investor Meeting Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors in New York on Wednesday, January...
SAN DIEGO , Dec. 30, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced it will be hosting a meeting for analysts and investors in New York on Wednesday, January 7, 2015 at 10:00 a.m. ET / 7:00 a.m. PT . During the meeting, Halozyme's senior manageme
Read more →HALOHalozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for Orphan...
SAN DIEGO , Dec. 19, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated PEGylated recom
Read more →HALOHalozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE™ Technology Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen...
SAN DIEGO , Dec. 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen Biotech, Inc. (Janssen) for the purpose of developing and commercializing products combining
Read more →HALOHalozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th ...
SAN DIEGO , Dec. 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37 th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentatio
Read more →HALOHalozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday, December ...
SAN DIEGO , Dec. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the 25 th Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 1:00 p.m. ET / 10:00 a.m. PT . David Ramsay , Vice President and Chief Fina
Read more →HALOHalozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014...
SAN DIEGO , Nov. 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 p.m. EDT / 10:00 a.m. PDT . Dr. Helen Torley , President and Chief Executive Offi
Read more →HALOInvestor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Media Contact: Susan Neath Francis 212-301-7182 sfrancis@w2ogroup.com HALOZYME REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS -Halozyme c
Halozyme Therapeutics sfrancis@w2ogroup.com HALOZYME REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS -Halozyme completes corporate strategy review and affirms priority focus on advancing PEGPH20 and ENHANZE - -New patient enrollment underway in Study 202 with 25 patients enrolle
Read more →HALOHalozyme Reports Third Quarter 2014 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial highlights for...
SAN DIEGO , Nov. 10, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the third quarter ended September 30, 2014 . Financial highlights for the third quarter include revenues of $14.6 million and a net loss of $20.3 million , o
Read more →HALOHalozyme to Host Third Quarter 2014 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014...
SAN DIEGO , Nov. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , President and Chief Executive Officer
Read more →HALOHalozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing...
SAN DIEGO , Oct. 20, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex ® recombinant (hyaluronidase human injection
Read more →HALOHalozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced an oral presentation on the pharmacology of PEGPH20 at the New York Academy of Sciences...
SAN DIEGO , Oct. 9, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced an oral presentation on the pharmacology of PEGPH20 at the New York Academy of Sciences symposium "Targeting Key Vulnerabilities in Pancreatic Cancer," being held on October 9, 20
Read more →HALOHalozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the issuance of U.S. Patent No. 8,846,034 claiming methods for selecting a subject for...
SAN DIEGO , Oct. 7, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the issuance of U.S. Patent No. 8,846,034 claiming methods for selecting a subject for treatment of a hyaluronan-associated disease with an anti-hyaluronan agent, such as PEGPH20,
Read more →HALOHalozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for...
SAN DIEGO , Oct. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer
Read more →HALOSWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient...
SAN DIEGO , Sept. 18, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313). T
Read more →HALOHalozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for...
SAN DIEGO , Sept. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase) in co
Read more →HALOInvestor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Media Contact: Susan Neath Francis 212-301-7182 sfrancis@wcgworld.com HALOZYME REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS - Patient
Halozyme Therapeutics sfrancis@wcgworld.com HALOZYME REPORTS SECOND QUARTER 2014 - Patient dosing and enrollment resumed for PEGPH20 Phase 2 clinical trial - - Commercial launch of MabThera SC triggered $5 million milestone payment - SAN DIEGO, August 11, 2014 -- Halozyme Th
Read more →HALOHalozyme Reports Second Quarter 2014 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the...
SAN DIEGO , Aug. 11, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the second quarter ended June 30, 2014 . Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million , or $
Read more →HALOHalozyme to Host second Quarter 2014 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014...
SAN DIEGO , Aug. 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , President and Chief Executive Officer,
Read more →HALOHalozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study...
SAN DIEGO , July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical pr
Read more →HALORoche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5 million milestone...
SAN DIEGO , June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that the commercial launch of MabThera ® SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agree
Read more →HALOHalozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY, on Tuesday, June 24,...
SAN DIEGO , June 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY , on Tuesday, June 24, 2014 at 2:30 p.m. ET / 11:30 a.m. PT . David Ramsay , Chief Financial Officer, will pro
Read more →HALOHalozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th Scientific...
SAN DIEGO , June 15, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th Scientific Sessions of the American Diabetes Association in San Francisco . The CONSISTENT 1 trial is
Read more →HALOHalozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient...
SAN DIEGO , June 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGP
Read more →HALOHalozyme Therapeutics To Present At The Jefferies 2014 Global Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2014 Global Health Care Conference in New York, NY, on Thursday, June...
SAN DIEGO , May 29, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Jefferies 2014 Global Health Care Conference in New York, NY , on Thursday, June 5, 2014 at 12:30 p.m. ET / 9:30 a.m. PT . Dr. Helen Torley , Chief Executive Officer, wi
Read more →HALOHalozyme Therapeutics To Present At The UBS 2014 Global Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2014 Global Health Care Conference in New York, NY, on Tuesday, May 20, 2014 ...
SAN DIEGO , May 14, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the UBS 2014 Global Health Care Conference in New York, NY , on Tuesday, May 20, 2014 at 3:00 p.m. ET / 12:00 p.m. PT . David Ramsay , Chief Financial Officer, will provide
Read more →HALOHalozyme Reports First Quarter 2014 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2014. Financial highlights for the...
SAN DIEGO , May 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the first quarter ended March 31, 2014 . Financial highlights for the first quarter include revenues of $12.0 million and a net loss of $26.5 million , or $0.
Read more →HALOInvestor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Media Contact: Denise Powell 510-703-9491 dpowell@brewlife.com HALOZYME REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Positive top-line
Halozyme Therapeutics dpowell@brewlife.com HALOZYME REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Positive top-line data from studies with HTI-501 in cellulite and Hylenex with insulin pumps SAN DIEGO, May 12, 2014 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported f
Read more →HALOHalozyme Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH20 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that as a result of a recommendation received yesterday from an independent Data...
SAN DIEGO , April 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in
Read more →HALOHalozyme Announces Appointment Of Oncology Product Team Leader And Other Executive Transitions Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Sunil Joshi as Vice President and Global Product Team Lead (GPTL), for...
SAN DIEGO , April 2, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the appointment of Sunil Joshi as Vice President and Global Product Team Lead (GPTL), for PEGPH20 and Oncology. With over 20 years of experience in the biopharmaceutical industry
Read more →HALOHalozyme Announces that Consistent 1 Trial Of Hylenex® Recombinant Met Primary Endpoint Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the...
SAN DIEGO , March 31, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex ® recombinant and a new formulation
Read more →HALOHalozyme Announces Roche Marketing Authorization For MabThera SC For Patients With Common Forms Of Non-Hodgkin Lymphoma In European Union Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation...
SAN DIEGO , March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera ® (rituximab) for the treatment of patients with follicular lymphoma and dif
Read more →HALOHalozyme Therapeutics To Present At The Barclays 2014 Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2014 Global Healthcare Conference in Miami, FL on March 11, 2014 at...
SAN DIEGO , March 5, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Barclays 2014 Global Healthcare Conference in Miami, FL on March 11, 2014 at 2:00 p.m. ET / 11:00 a.m. PT . Dr. Helen Torley , President and Chief Executive Officer, wi
Read more →HALOInvestor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Media Contact: Nurha Hindi Hill + Knowlton Strategies 310-633-9434 Nurha.Hindi@hkstrategies.com HALOZYME REPORTS FOURTH QUARTER AND YEA
Halozyme Therapeutics Hill + Knowlton Strategies Nurha.Hindi@hkstrategies.com HALOZYME REPORTS FOURTH QUARTER AND YEAR END 2013 SAN DIEGO, February 27, 2014 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year end
Read more →HALOHalozyme Reports Fourth Quarter And Year End 2013 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2013. Financial...
SAN DIEGO , Feb. 27, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the fourth quarter and full year ended December 31, 2013 . Financial highlights for the fourth quarter include revenues of $12.5 million and a net loss of $2
Read more →HALOHalozyme Therapeutics To Present At The Cowen And Company 34th Annual Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Cowen and Company 34th Annual Healthcare Conference in Boston, MA on Tuesday,...
SAN DIEGO , Feb. 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Cowen and Company 34 th Annual Healthcare Conference in Boston, MA on Tuesday, March 4, 2014 at 9:20 a.m. ET / 6:20 a.m. PT . David Ramsay , Chief Financial Officer, wi
Read more →HALOHalozyme to Host Fourth Quarter and 2013 Year-End Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2013 on Thursday,...
SAN DIEGO , Feb. 20, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2013 on Thursday, February 27, 2014 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , President and Chief
Read more →HALOHalozyme Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the closing of its previously announced public offering of 8,846,153 shares of common...
SAN DIEGO , Feb. 10, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today the closing of its previously announced public offering of 8,846,153 shares of common stock, including 1,153,846 shares sold pursuant to the underwriters' full exercise of their
Read more →HALOHalozyme Therapeutics Prices Public Offering Of Common Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the pricing of its previously announced underwritten public offering of 7,692,307 shares...
SAN DIEGO , Feb. 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today the pricing of its previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share. All of the shares in t
Read more →HALOInvestor and Media Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com
HALOZYME THERAPEUTICS ANNOUNCES PUBLIC OFFERING February 3, 2014 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares in the offering are to be sold by H
Read more →HALOHalozyme Announces Positive Opinion From CHMP For European Approval Of Roche's MabThera SC Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the ...
SAN DIEGO , Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera ® (rituxi
Read more →HALOHalozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on the anticipated milestones for its product development programs in 2014....
SAN DIEGO , Jan. 13, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today provided an update on the anticipated milestones for its product development programs in 2014. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "Halozyme is poised for a p
Read more →HALOHill + Knowlton Strategies
Halozyme Therapeutics Hill + Knowlton Strategies Nurha.Hindi@hkstrategies.com HALOZYME THERAPEUTICS PROVIDES AN UPDATE ON ANTICIPATED MILESTONES FOR 2014 AT THE 32ND ANNUAL J. P. MORGAN HEALTHCARE CONFERENCE SAN DIEGO, January 13, 2014 - Halozyme Therapeutics, Inc. (NASDAQ: H
Read more →HALOHalozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday,...
SAN DIEGO , Jan. 9, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2014 at 10:00 a.m. PT / 1:00 p.m. ET . Helen Torley , M.B. Ch. B., M.R.C.P., Pres
Read more →HALOHalozyme Secures Additional $20 Million Term Loan Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it secured an additional $20 million loan from Oxford Finance and Silicon Valley Bank. On...
SAN DIEGO , Jan. 6, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced it secured an additional $20 million loan from Oxford Finance and Silicon Valley Bank. On December 27, 2013 , Halozyme entered into an Amended and Restated Loan and Security Agree
Read more →HALOInvestor Contact: David Ramsay Halozyme Therapeutics 858-704-8260 ir@halozyme.com Media Contact: Tali Mackay Hill+Knowlton Strategies 310-633-9495 Tali.Mackay@hkstrategies.com FOR IMMEDIATE RELEASE Halozyme Therapeutics
Halozyme Therapeutics Hill+Knowlton Strategies Tali.Mackay@hkstrategies.com Halozyme Therapeutics Announces Executive Transitions Helen Torley to assume role of President and CEO; Gregory I. Frost to lead Intrexon's Health Sector and will remain on Halozyme's Scientific Advis
Read more →HALOHalozyme Therapeutics Announces Executive Transitions Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Helen Torley, M.B. Ch. B., M.R.C.P., will be joining Halozyme as President and Chief...
SAN DIEGO , Dec. 17, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that Helen Torley , M.B. Ch. B., M.R.C.P., will be joining Halozyme as President and Chief Executive Officer on January 6, 2014 . She will also become a member of Halozyme's Boar
Read more →HALOHalozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2013 at...
SAN DIEGO , Nov. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2013 at 12:00 p.m. ET / 9:00 a.m. PT . Gregory I. Frost , Ph.D., President and Chief Executive O
Read more →HALOInvestor Contact: David Ramsay Halozyme Therapeutics 858-704-8260 ir@halozyme.com Media Contact: Nurha Hindi Hill + Knowlton Strategies 310-633-9434 Nurha.Hindi@hkstrategies.com Halozyme Reports Third Quarter 2013 Financ
Halozyme Therapeutics Hill + Knowlton Strategies Nurha.Hindi@hkstrategies.com Halozyme Reports Third Quarter 2013 Financial Results SAN DIEGO, November 8, 2013 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter and nine months
Read more →HALOHalozyme Reports Third Quarter 2013 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter and nine months ended September 30, 2013. Financial ...
SAN DIEGO , Nov. 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the third quarter and nine months ended September 30, 2013 . Financial highlights for the third quarter include revenues of $16.0 million and a net loss of $1
Read more →HALOHalozyme to Host Third Quarter 2013 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2013 on Friday, November 8, 2013...
SAN DIEGO , Nov. 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the third quarter 2013 on Friday, November 8, 2013 at 8:30 a.m. ET / 5:30 a.m. PT . Gregory I. Frost , President and Chief Executive Officer,
Read more →HALOSWOG Initiates Randomized Phase 2 Clinical Trial of Halozyme's PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the initiation of a Phase 1b/2 randomized clinical trial (S1313) of Halozyme's...
SAN DIEGO , Oct. 22, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the initiation of a Phase 1b/2 randomized clinical trial (S1313) of Halozyme's investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with modifi
Read more →HALOYale Researchers Initiate Clinical Trial Evaluating Halozyme's Recombinant Hyaluronidase in Artificial Pancreas Study Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the first patient has been dosed in a closed loop control ( artificial pancreas ) clinical ...
SAN DIEGO , Oct. 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today the first patient has been dosed in a closed loop control ("artificial pancreas") clinical study involving Halozyme's recombinant human hyaluronidase being performed by researche
Read more →HALOCommercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the commercial launch of Herceptin® SC in Europe has triggered a $10 million...
SAN DIEGO , Sept. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the commercial launch of Herceptin ® SC in Europe has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme a
Read more →HALOHalozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the BioCentury Newsmakers in the Biotech Industry Conference in New York on Friday,...
SAN DIEGO , Sept. 20, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the BioCentury Newsmakers in the Biotech Industry Conference in New York on Friday, Sept. 27, 2013 at 8:30 a.m. ET / 5:30 a.m. PT . Gregory I. Frost , President and Chief
Read more →HALOHalozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated recombinant human...
SAN DIEGO , Sept. 12, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metas
Read more →HALOHalozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission has granted Roche European Union (EU) marketing authorization ...
SAN DIEGO , Sept. 2, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin ® (trastuzumab)
Read more →HALOInvestor Contact: David Ramsay Halozyme Therapeutics 858-704-8260 ir@halozyme.com Media Contact: Nurha Hindi Hill + Knowlton Strategies 310-633-9434 Nurha.Hindi@hkstrategies.com Halozyme Reports Second Quarter 2013 Finan
Halozyme Therapeutics Hill + Knowlton Strategies Nurha.Hindi@hkstrategies.com Halozyme Reports Second Quarter 2013 Financial Results SAN DIEGO, August 7, 2013 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter and six months ended J
Read more →HALOHalozyme Reports Second Quarter 2013 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter and six months ended June 30, 2013. Financial highlights...
SAN DIEGO , Aug. 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the quarter and six months ended June 30, 2013 . Financial highlights for the second quarter include revenues of $14.5 million and a net loss of $22.9 million
Read more →HALOHalozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that following discussions with the Center for Biologics Evaluation and Research (CBER) division ...
SAN DIEGO , Aug. 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced that following discussions with the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food and Drug Administration, ViroPharma will be discontinuing their Phase 2
Read more →HALOHalozyme to Host Second Quarter 2013 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2013 on Wednesday, August 7, 2013 ...
SAN DIEGO , July 31, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the second quarter 2013 on Wednesday, August 7, 2013 at 4:30 p.m. ET / 1:30 p.m. PT . Gregory I. Frost , President and Chief Executive Offic
Read more →HALOGYNOID LIPODYSTROPHY (CELLULITE): A PHASE 1/ 2, VEHICLE-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOLOGIC EFFECT OF SUBCUTANEOUSLY INJECTED RHUCAT-L IN HEALTHY FEMALE SUBJECTS (PRELIMINARY INTERIM RESUL
LIPODYSTROPHY (CELLULITE): A PHASE 1/ 2, VEHICLE-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOLOGIC EFFECT OF SUBCUTANEOUSLY INJECTED RHUCAT-L IN HEALTHY FEMALE SUBJECTS (PRELIMINARY INTERIM RESULTS) DR. FRANCISCO PEREZ ATAMOROS DERMATOLOGIST amdac@iwm.com.mx D
Read more →HALOHalozyme Presents New HTI-501 Data Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced interim results from a proof of concept Phase 1/2 clinical trial evaluating the activity...
SAN DIEGO , June 30, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced interim results from a proof of concept Phase 1/2 clinical trial evaluating the activity and local tolerability of HTI-501, an investigational biologic, for use in aesthetic derm
Read more →HALOHalozyme Announces Positive Opinion from CHMP On Roche's Herceptin SC for European Approval Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Roche received a positive recommendation from the European Medicines Agency's...
SAN DIEGO , June 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that Roche received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the subcutaneous formulation of Herce
Read more →HALOHalozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced results from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an...
SAN DIEGO , June 3, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced results from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for the treatment of patient
Read more →HALOHalozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer SAN DIEGO, May 23, 2013 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of David A. Ramsay as Chief Financial Officer. Mr. Ramsay was most recently Vice President, Corporate Develop
Read more →HALOHalozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human...
SAN DIEGO , May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of
Read more →HALOHalozyme Reports First Quarter 2013 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2013. (Logo:...
SAN DIEGO , May 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the quarter ended March 31, 2013 . (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "With the potential for 3 new product launches over the ne
Read more →HALOHalozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on...
SAN DIEGO , May 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on Tuesday, May 14, 2013 at 1:40 p.m. PT / 4:40 p.m. ET . Kurt Gustafson , Chief Financial Officer,
Read more →HALOHalozyme to Host First Quarter 2013 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2013 on Wednesday, May 8, 2013 at...
SAN DIEGO , May 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the first quarter 2013 on Wednesday, May 8, 2013 at 4:30 p.m. ET / 1:30 p.m. PT . Gregory I. Frost , President and Chief Executive Officer, wi
Read more →HALOHalozyme Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic Cancer Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20, a...
SAN DIEGO , April 23, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20, a proprietary, investigational drug, as a first-line therapy for patients with stage IV me
Read more →HALOHalozyme Therapeutics Names Matt Posard to Board of Directors Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Matt Posard to its Board of Directors. Mr. Posard is currently Senior...
SAN DIEGO , March 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the appointment of Matt Posard to its Board of Directors. Mr. Posard is currently Senior Vice President and General Manager of Translational & Consumer Genomics at Illumina, Inc
Read more →HALOBaxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union Baxter International Inc. (NYSE: BAX) and Halozyme Therapeutics, Inc., (NASDAQ: HALO) today announced that the European Medicines Agency's Committee...
LONDON , March 22, 2013 /PRNewswire/ -- Baxter International Inc. (NYSE: BAX ) and Halozyme Therapeutics, Inc., (NASDAQ: HALO ) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) has granted a Positive Opinion to Baxter
Read more →HALOHalozyme Reports Fourth Quarter and Year End 2012 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and year ended December 31, 2012. (Logo:...
SAN DIEGO , Feb. 25, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the fourth quarter and year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "2012 was another productive year mark
Read more →HALOInvestor Contact: Kurt Gustafson Halozyme Therapeutics 858-704-8272 ir@halozyme.com Media Contact: Nurha Hindi Hill + Knowlton Strategies 310-633-9434 Nurha.Hindi@hkstrategies.com Halozyme Reports Fourth Quarter and Year
Halozyme Therapeutics Hill + Knowlton Strategies Nurha.Hindi@hkstrategies.com Halozyme Reports Fourth Quarter and Year End 2012 Financial Results SAN DIEGO, February 25, 2013 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter
Read more →HALOHalozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2012 on Monday,...
SAN DIEGO , Feb. 19, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2012 on Monday, February 25, 2013 at 4:30 p.m. ET / 1:30 p.m. PT . Gregory I. Frost , Ph.D., President and
Read more →HALOHalozyme Therapeutics Issues Financial Guidance For 2013 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company dedicated to developing and commercializing innovative products that advance...
SAN DIEGO , Jan. 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care, today announced that the Company ended 2012 with a cash balance of approxim
Read more →HALOHalozyme Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday,...
SAN DIEGO , Jan. 3, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the 31 st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2013 at 10:00 a.m. PT / 1:00 p.m. ET . Gregory I. Frost , President and Chief Ex
Read more →HALOHalozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc....
SAN DIEGO , Dec. 21, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (NYSE: PFE ) for the purpose of developing and commercializing products combining propri
Read more →HALOHalozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Roche has submitted a line extension application to the European Medicines Agency for ...
SAN DIEGO , Dec. 8, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Roche has submitted a line extension application to the European Medicines Agency for a subcutaneous (SC) formulation of MabThera ® (rituxumab). The filing of the application
Read more →HALOHalozyme Reports Third Quarter 2012 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended September 30, 2012. (Logo: http://photos.prnewswire....
SAN DIEGO , Nov. 8, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the quarter ended September 30, 2012 . (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "We are pleased with the clinical data from the subcu
Read more →HALOHalozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference in New York on Tuesday,...
SAN DIEGO , Nov. 6, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Lazard Capital Markets 9 th Annual Healthcare Conference in New York on Tuesday, November 13, 2012 at 1:30 p.m. PT / 4:30 p.m. ET . Kurt Gustafson , Chief Financial Offi
Read more →HALOHalozyme to Host Third Quarter Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2012 on Thursday, November 8, 2012 ...
SAN DIEGO , Nov. 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the third quarter 2012 on Thursday, November 8, 2012 at 4:30 p.m. ET / 1:30 p.m. PT . Gregory I. Frost , President and Chief Executive Office
Read more →HALOSafe harbor All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These f
Herceptin trastuzumab MabThera rituximab MabThera rituximab Herceptin trastuzumab Herceptin trastuzumab Gregory I. Frost, Ph.D. Closing Remarks Milestones (for proprietary and partnered programs) Present full data set from Phase 3 Herceptin SC trial File Herceptin SC marketing ap
Read more →HALOHalozyme Therapeutics to Host Analyst / Investor Meeting on October 2nd in New York Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors on October 2, 2012 in New York....
SAN DIEGO , Sept. 25, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced it will be hosting a meeting for analysts and investors on October 2, 2012 in New York . During the meeting, Halozyme's senior management, as well as external advisors to the Co
Read more →HALOHalozyme Reports Second Quarter 2012 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended June 30, 2012. (Logo:...
SAN DIEGO , Aug. 6, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the quarter ended June 30, 2012 . (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "With receipt of the complete response letter for the HyQ
Read more →HALOHalozyme to Host Second Quarter Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter on Monday, August 6, 2012 at 4:30 ...
SAN DIEGO , Aug. 2, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the second quarter on Monday, August 6, 2012 at 4:30 p.m. ET / 1:30 p.m. PT . Gregory I. Frost , President and Chief Executive Officer, will
Read more →HALOHalozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced results from a Phase 2 study of prandial insulin formulations, which include the Company's ...
PHILADELPHIA , June 11, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes.
Read more →HALOHalozyme Presents Positive Data from Two Ultrafast Insulin Clinical Trials with Human Hyaluronidase Enzyme - rHuPH20 - at ADA 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of two posters at the 72nd Scientific Sessions of the American Diabetes...
PHILADELPHIA , June 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the presentation of two posters at the 72nd Scientific Sessions of the American Diabetes Association (ADA) highlighting its research on improved treatment options for both the
Read more →HALOInterim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile: Data Presented in Late-Breaker Poster at ADA 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented results from a Phase 4 study of Hylenex® recombinant (hyaluronidase human injection) in...
PHILADELPHIA , June 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today presented results from a Phase 4 study of Hylenex ® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabe
Read more →HALOHalozyme Therapeutics to Present New Data on the Company's Ultrafast Insulin Programs at ADA 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Company will present data from its diabetes studies for both multiple daily...
SAN DIEGO , June 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the Company will present data from its diabetes studies for both multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) Ultrafast Insulin program
Read more →HALOHalozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7,...
SAN DIEGO , May 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 12:30 p.m. ET / 9:30 a.m. PT . Kurt Gustafson , Chief Financial Officer, Halozyme Th
Read more →HALOHalozyme Therapeutics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas on...
SAN DIEGO , May 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas on Wednesday, May 16, 2012 at 10:00 a.m. PT / 1:00 p.m. ET . Gregory I. Frost , Ph.D., President an
Read more →HALOHalozyme Reports First Quarter 2012 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2012. (Logo:...
SAN DIEGO , May 7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the quarter ended March 31, 2012 . (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) "We achieved a significant milestone in the first quarter
Read more →HALOHalozyme to Host First Quarter 2012 Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at...
SAN DIEGO , April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET / 1:30 p.m. PT . Gregory I. Frost , President and Chief Executive Officer, wi
Read more →HALOBaxter and Halozyme Provide Update on HyQ Biologics License Application Baxter International Inc. (NYSE: BAX) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) ...
DEERFIELD, Ill. and SAN DIEGO, Calif. , April 16, 2012 /PRNewswire/ -- Baxter International Inc. (NYSE: BAX ) and Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the U.S. Food and Drug Administration (FDA) is requesting additional information to complete its revi
Read more →HALOHalozyme Reports Fourth Quarter and Year End 2011 Financial Results and Provides Guidance for 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter and year ended December 31, 2011, and announced that...
SAN DIEGO , March 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results for the quarter and year ended December 31, 2011 , and announced that Roche has submitted a Line Extension Application to the European Medicines Agency (EMA) for
Read more →HALOMedia/Investor Contact: Anne Erickson Executive Director Halozyme Therapeutics 858-704-8264 aerickson@halozyme.com HALOZYME REPORTS FOURTH QUARTER AND YEAR END 2011 FINANCIAL RESULTS AND PROVIDES GUIDANCE FOR 2012 Compan
HALOZYME REPORTS FOURTH QUARTER AND YEAR END 2011 FINANCIAL RESULTS AND PROVIDES GUIDANCE FOR 2012 Company Announces Roche Submission of a Line Extension Application for Subcutaneous Herceptin, Triggering a $4 Million Milestone Payment March 9, 2012 Halozyme Therapeutics, Inc
Read more →HALOHalozyme Therapeutics to Present at Two Upcoming Investor Conferences in March Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March: 24th Annual Roth Conference in Dana ...
SAN DIEGO , March 7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the following two investor conferences in March: (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) The presentations will be webcast through the "Investors"
Read more →HALOHalozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2011 on Friday,...
SAN DIEGO , March 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2011 on Friday, March 9, 2012 at 8:00 a.m. ET / 5:00 a.m. PT . Greg I. Frost , President and Chief Executiv
Read more →HALOHalozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Citi 2012 Global Healthcare Conference in New York on Wednesday, February 29,...
SAN DIEGO , Feb. 22, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the Citi 2012 Global Healthcare Conference in New York on Wednesday, February 29, 2012 at 11:00 a.m. ET / 8:00 a.m. PT . Kurt Gustafson , Chief Financial Officer, Halozyme
Read more →HALOHalozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the completion of an underwritten public offering of 7,820,000 shares of its common stock, ...
SAN DIEGO , Feb. 15, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the completion of an underwritten public offering of 7,820,000 shares of its common stock, including 1,020,000 shares sold pursuant to the full exercise of an over-allotment opti
Read more →HALOHalozyme Announces Pricing of Public Offering of Common Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at...
SAN DIEGO , Feb. 10, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a price to the public of $10.61 per share. The offering is expected to settle and close
Read more →HALOHalozyme Announces Proposed Public Offering of Common Stock Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is offering to sell 6,800,000 shares of its common stock pursuant to an effective...
SAN DIEGO , Feb. 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that it is offering to sell 6,800,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital Inc. is
Read more →HALOMedia/Investor Contact: Anne Erickson Executive Director Halozyme Therapeutics 858-704-8264 aerickson@halozyme.com
HALOZYME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, February 9, 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is offering to sell 6,800,000 shares of its common stock pursuant to an effective shelf registration statement in an underw
Read more →HALOHTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented interim results from the Phase 1 proof-of-concept and local tolerability study of HTI-501...
SAN DIEGO , Jan. 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today presented interim results from the Phase 1 proof-of-concept and local tolerability study of HTI-501 (an investigational, conditionally active recombinant human cathepsin) at the 8th World
Read more →HALOHalozyme Therapeutics, Inc. Thinking Outside the Cell(tm) J.P. Morgan Healthcare Conference
Our proprietary programs leverage our ability to enhance drug efficacy and unveil new opportunities Hylenex Low dose rHuPH20 approved for dispersion and absorption of drugs and fluids Ultrafast Insulin Analog insulin formulated with rHuPH20 for treatment of diabetes PEGPH20 PEGyl
Read more →HALOHalozyme Therapeutics to Present at the Oppenheimer Annual Healthcare Conference on December 13 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Dec. 7, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at the Oppenheimer Annual Healthcare C
Read more →HALOHalozyme Therapeutics to Host Third Quarter 2011 Financial Results Conference Call on November 7 Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Nov. 2, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced it plans to report third quarter 2011 financial results on Monday, Novemb
Read more →HALOHalozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix...
SAN DIEGO , Oct. 27, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced clinical
Read more →HALOHalozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Oct. 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , for the diabetes, cancer, dermatology and drug delivery markets, today announced its upc
Read more →HALOHalozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials in Patients with Type 1 and Type 2 Diabetes Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix...
SAN DIEGO , Oct. 21, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive
Read more →HALOHalozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix...
SAN DIEGO , Sept. 28, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the comm
Read more →HALOHalozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Sept. 22, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at the JMP Securities Healthcare Con
Read more →HALOHalozyme Therapeutics to Present at Upcoming Financial Conferences Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Sept. 1, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at two upcoming financial conferences
Read more →HALOHalozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Aug. 12, 2011 / PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at the Wedbush 2011 Life Sciences Co
Read more →HALOHalozyme Therapeutics Reports Second Quarter 2011 Financial Results Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix...
SAN DIEGO , Aug. 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial r
Read more →HALOHalozyme Therapeutics to Host Second Quarter 2011 Financial Results Conference Call on August 5 Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Aug. 1, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced it plans to report second quarter 2011 financial results on Friday, Augus
Read more →HALOHalozyme's Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced final results from a study in type 1 diabetes patients who receive their insulin treatment ...
SAN DIEGO , June 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced final results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 (recomb
Read more →HALOHalozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , June 20, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced three upcoming data presentations for it Ultrafast Insulin programs at t
Read more →HALOHalozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the ...
SAN DIEGO and FOSTER CITY, Calif. , June 6, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the developm
Read more →HALOHalozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9 Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , June 2, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at the Jefferies 2011 Global Healthcar
Read more →HALOHalozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human]) Halozyme Therapeutics, Inc. (Nasdaq: HALO) and ViroPharma Incorporated (Nasdaq: VPHM), today announced the signing of a worldwide exclusive licensing ...
SAN DIEGO , May 11, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) and ViroPharma Incorporated (Nasdaq: VPHM ), today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the development o
Read more →HALOHalozyme Therapeutics Reports First Quarter 2011 Financial Results Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix...
SAN DIEGO , May 6, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial re
Read more →HALOHalozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12 Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , May 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at the Bank of America Merrill Lynch He
Read more →HALOHalozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , April 29, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced it plans to report first quarter 2011 financial results on Friday, May
Read more →HALOHalozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced results from a study in type 1 diabetes patients who receive their insulin treatment with...
SAN DIEGO , April 14, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant
Read more →HALOHalozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix...
SAN DIEGO , March 11, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported fi
Read more →HALOHalozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11 Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , March 4, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced it plans to report fourth quarter and 2010 financial results on Friday M
Read more →HALOHalozyme Therapeutics to Present at Two Investor Conferences in March Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , March 1, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at two investor conferences during Ma
Read more →HALOHalozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC)...
SAN DIEGO , Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) and Roche (SIX: RO, ROG; OTCQX: RHHBY ) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze(™
Read more →HALOHalozyme Announces Roche Completes Patient Enrollment in Phase 3 Clinical Trial with Subcutaneous Herceptin® Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC...
SAN DIEGO , Dec. 7, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enh
Read more →HALOHalozyme Therapeutics Realigns Management Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Dec. 3, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced the appointment of Gregory I. Frost , Ph.D., to serve as presid
Read more →HALOHalozyme Therapeutics to Present at Upcoming Investor Conference Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Dec. 1, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at the 5th Annual Canaccord
Read more →HALOHalozyme's rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced Phase 2 results demonstrating that Insulin-PH20 (recombinant human insulin with rHuPH20)...
SAN DIEGO , Nov. 12, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced Phase 2 results demonstrating that Insulin-PH20 (recombinant human insulin with rHuPH20) produced glycemic control comparable to lispro, a widely prescribed prandial (m
Read more →HALOHalozyme Therapeutics Reports Third Quarter 2010 Financial Results Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix...
SAN DIEGO , Nov. 5, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today rep
Read more →HALOHalozyme Therapeutics Awarded Four Qualifying Therapeutic Discovery Project Grants Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Nov. 4, 2010 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced the award of four grants totaling $977,917 under the Qualifying Therapeut
Read more →HALOHalozyme Therapeutics Announces Hiring of New Leadership for Business Development Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Oct. 28 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that William F. Daly has joined the company as vice president of bus
Read more →HALOHalozyme Therapeutics to Host Third Quarter Conference Call on November 5 and Present at Two Upcoming Investor Conferences Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Oct. 26 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced it plans to report third quarter 2010 financial results on Friday No
Read more →HALOHalozyme Therapeutics Announces Implementation of Development Focused Strategy Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Oct. 11 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced a focusing of its resources on advancing its core proprietary progra
Read more →HALOHalozyme Therapeutics to Host Analyst Meeting on October 14 in New York Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Oct. 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 14,
Read more →HALOHalozyme Therapeutics to Present at Two Upcoming Investor Conferences Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix,...
SAN DIEGO , Sept. 15 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix , today announced that management will be presenting at two investor conferences duri
Read more →HALOHalozyme Therapeutics Announces Pricing of Public Offering of Common Stock Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the pricing of its previously announced public offering of 8.3 million shares of its...
SAN DIEGO , Sept. 9 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced the pricing of its previously announced public offering of 8.3 million shares of its common stock at a price to the public of $7.50 per share. The offering is expected to set
Read more →HALOHalozyme Therapeutics Announces Public Offering of Common Stock Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced that it is offering to sell 8.3 million shares of its common stock pursuant to an...
SAN DIEGO , Sept. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced that it is offering to sell 8.3 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital
Read more →HALOHalozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro and Aspart With rHuPH20 in Type 1 and Type 2 Diabetes Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 ...
SAN DIEGO , Sept. 2 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealti
Read more →HALOHalozyme Provides HYLENEX® Product Reintroduction Update Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has...
SAN DIEGO , Aug. 31 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market.
Read more →HALOHalozyme Announces Issuance of U.S. Patent for rHuPH20 Enzyme Platform Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human...
SAN DIEGO , Aug. 12 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human hyaluronidase enzyme platform (rHuPH20). Claims to the human PH20 glycoprotein, PEGylated
Read more →HALOHalozyme Therapeutics Reports Second Quarter 2010 Financial Results Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix...
SAN DIEGO , Aug. 6 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported
Read more →HALOHalozyme Therapeutics Presents Positive Pre-Clinical Single Agent Data for PEGPH20
Halozyme Therapeutics presented positive pre-clinical data for PEGPH20, showing a 70% tumor growth inhibition in the PC3 mouse model. The results suggest that PEGPH20 may enable new treatment strategies for prostate cancer by depleting hyaluronan in the tumor microenvironment. The company plans to initiate a Phase 1 clinical trial in treatment-refractory cancer patients in 2009.
Read more →HALOHalozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial With Second Biologic
Halozyme Therapeutics announced that Roche has begun a Phase 1 clinical trial using its Enhanze Technology for a new biologic target. This marks the second trial initiated by Roche in a short period, highlighting their efficient development approach. The collaboration could yield additional milestone payments and royalties for Halozyme, contingent on successful outcomes.
Read more →HALOHalozyme to Present At J.P. Morgan Healthcare Conference
Halozyme Therapeutics, Inc. announced that its President and CEO, Jonathan Lim, M.D., will present at the J.P. Morgan 27th Annual Healthcare Conference on January 15, 2009. The presentation will focus on Halozyme's innovative products targeting the extracellular matrix across various medical fields. Interested parties can access the live webcast and archived presentation on Halozyme's website.
Read more →Competitive Position
How HALO ranks across every disease it competes inCompetitive Position is a premium feature
See how HALO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial